|
☐ TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For
the transition period from _______ to________
|
Delaware
|
04-2217279
|
(State or other jurisdiction of incorporation or
organization)
|
(I.R.S.
Employer Identification No.)
|
|
|
80 Orville Drive, Suite 102, Bohemia, New York
|
11716
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Name of each exchange on which registered
|
None
|
None
|
Title of Class
|
Common stock, $.05 par value
|
Large
accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☐ (Do
not check if a smaller reporting company)
|
Smaller reporting company ☒
|
Emerging Growth ☐
|
|
Indicate by check mark whether the registrant is a shell
company (as
defined in Rule 12b-2 of the Act) ☐ Yes ☒ No
|
|
PART I
|
|
|
|
|
|
Item 1.
|
BUSINESS
|
4
|
|
|
|
Item 1A.
|
RISK
FACTORS
|
8
|
|
|
|
Item 2.
|
PROPERTIES
|
12
|
|
|
|
Item 3.
|
LEGAL PROCEEDINGS
|
12
|
|
|
|
Item 4.
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
12
|
|
|
|
PART II
|
||
|
|
|
Item 5.
|
MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES
|
13
|
|
|
|
Item 7.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
|
14
|
|
|
|
Item 8.
|
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
17
|
|
|
|
Item 9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
|
17
|
|
|
|
Item 9A.
|
CONTROLS
AND PROCEDURES
|
17
|
|
|
|
Item 9B.
|
OTHER
INFORMATION
|
17
|
|
|
|
PART III
|
|
|
|
|
|
Item 10.
|
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
18
|
|
|
|
Item 11.
|
EXECUTIVE COMPENSATION
|
19
|
|
|
|
Item 12.
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
|
24
|
|
|
|
Item 13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
INDEPENDENCE
|
26
|
|
|
|
Item 14.
|
PRINCIPAL ACCOUNTANT FEES AND SERVICES
|
26
|
|
|
|
PART IV
|
|
|
|
|
|
Item 15.
|
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
|
26
|
|
|
|
SIGNATURES
|
|
35
|
|
|
|
EXHIBIT 31.0
|
CERTIFICATION
|
36
|
|
|
|
EXHIBIT 32.0
|
CERTIFICATION
|
37
|
For Fiscal Quarter Ended
|
Low
Bid
|
High
Bid
|
09/30/18
|
2.82
|
3.24
|
12/31/18
|
2.99
|
4.00
|
03/31/19
|
3.50
|
4.50
|
06/30/19
|
3.88
|
4.75
|
09/30/19
|
4.00
|
6.88
|
12/31/19
|
6.01
|
9.10
|
03/31/20
|
6.56
|
10.20
|
06/30/20
|
5.55
|
10.61
|
Name
and Principal Position
(a)
|
Fiscal
Year (b)
|
Salary
($)
(c)
|
Bonus
($)
(d)
|
Stock
Awards ($)
(e)
|
Option
Awards ($)
(f)
|
Non-
Equity Incentive Plan Compensation ($)
(g)
|
Non-
Qualified Deferred Compensation
Earnings
($)
(h)
|
Changes
in Pension Value and Non-Qualified Deferred
Compensation Earnings
|
All
Other Compensation ($)
(i)
|
Total
($)
(j)
|
Helena
R. Santos,
CEO,
President, CFO
|
2020
|
185,700
|
50,000
|
0
|
13,100(1)
|
0
|
0
|
0
|
9,400(6)
|
258,200
|
Helena
R. Santos,
CEO,
President, CFO
|
2019
|
180,300
|
0
|
0
|
13,100(1)
|
0
|
0
|
0
|
4,900(6)
|
198,300
|
|
|
|
|
|
|
|
|
|
|
|
John
A. Moore,
President
of
SBI
|
2020
|
145,000
|
50,000
|
0
|
36,000(2)
|
0
|
0
|
0
|
28,900(7)
|
259,900
|
John
A. Moore,
President
of
SBI
|
2019
|
40,000
|
0
|
0
|
12,000(2)
|
0
|
0
|
0
|
9,800(7)
|
61,800
|
|
|
|
|
|
|
|
|
|
|
|
Anthony
Mitri,
President
of Altamira
|
2020
|
130,000
|
0
|
0
|
6,500(3)
|
0
|
0
|
0
|
5,200(6)
|
141,700
|
Anthony
Mitri,
President
of Altamira
|
2019
|
120,000
|
0
|
0
|
6,500(3)
|
0
|
0
|
0
|
4,800(6)
|
131,300
|
|
|
|
|
|
|
|
|
|
|
|
Robert
P. Nichols,
President
of Genie Division
|
2020
|
162,300
|
5,000
|
0
|
3,900(4)
|
0
|
0
|
0
|
6,700(6)
|
177,900
|
Robert
P. Nichols,
President
of Genie Division
|
2019
|
157,600
|
0
|
0
|
3,900(4)
|
0
|
0
|
0
|
6,800(6)
|
168,300
|
|
|
|
|
|
|
|
|
|
|
|
Karl
D. Nowosielski
President
of Torbal Division and Director of Marketing
|
2020
|
169,800
|
10,000
|
0
|
6,300(5)
|
0
|
0
|
0
|
7,200(6)
|
193,300
|
Karl
D. Nowosielski
President
of Torbal Division and Director of Marketing
|
2019
|
163,300
|
10,000
|
0
|
7,400(5)
|
0
|
0
|
0
|
6,400(6)
|
187,100
|
Name
(a)
|
Grant
Date
(b)
|
Estimate Future
Payouts
Under
Non-Equity
Incentive
Plan
$
(c)
|
Estimated
Future
Payouts
Under
Equity
Incentive
Plan
$
(d)
|
All
Other
Stock
Awards
Number
Of
Shares
Of
Stock
Or
Units
(#)
(e)
|
All
Other
Option
Awards:
Number
Of
Securities
Underlying
Options
(#)
(f)
|
Exercise
Or
Base
Price
Of
Option
Awards
($/Sh)
(g)
|
Grant
Date
Fair
Value of
Stock
And
Option
Awards
(h)
|
John A.
Moore
|
07/01/19-
06/30/20
|
0
|
0
|
0
|
5,881
|
5.35-11.30
|
36,000
|
Option Awards
|
|||||
Name
(a)
|
Number of
Securities
Underlying
Unexercised
Options
(#) Exercisable
(b)
|
Number of
Securities
Underlying Unexercised
Options
(#)
Unexercisable
(c)
|
Equity
Incentive Plan Awards
Number
of Securities Underlying Unexercised Unearned Options
(#)
(d)
|
Option
Exercise
Price
($)
(e)
|
Option
Expiration
Date
(f)
|
Helena
Santos
|
8,666
|
8,334
|
0
|
3.08
|
07/2027
|
Anthony
Mitri
|
6,668
|
3,332
|
0
|
3.05-3.15
|
12/2027-06/2028
|
John
A. Moore
|
1,902
|
10,684
|
0
|
4.50-11.30
|
03/2029-06/2030
|
Robert
Nichols
|
5,000
|
2,500
|
0
|
3.08
|
12/2023-07/2027
|
Karl
Nowosielski
|
22,000
|
2,500
|
0
|
3.05-4.05
|
02/2024-07/2027
|
Name
(a)
|
Fees
Earned
or Paid
in Cash
($)
(b)
|
Stock Awards
($)
(c)
|
Option Awards
($)
(d)
|
Non-Equity Incentive Plan
Comp-
Ensation
($)
(e)
|
Changes
in
Pension Value and Non-qualified Deferred Compensation
Earnings
($)
(f)
|
Non-qualified Deferred Comp-sensation
Earnings
($)
(g)
|
All
Other
Comp- ensation
($)
(h)
|
Total
($)
(i)
|
Joseph
G. Cremonese
|
36,700
|
0
|
0
|
0
|
0
|
0
|
76,200(1)
|
112,900
|
Marcus
Frampton
|
24,800
|
0
|
0
|
0
|
0
|
0
|
0
|
24,800
|
John A. Moore (2)
|
|
|
|
|
|
|
|
|
Grace
S. Morin
|
6,400
|
0
|
0
|
0
|
0
|
0
|
8,400(3)
|
14,800
|
James
S. Segasture
|
16,800
|
0
|
0
|
0
|
0
|
0
|
0
|
16,800
|
John
F.F. Watkins
|
24,800
|
0
|
0
|
0
|
0
|
0
|
0
|
24,800
|
Name
|
Amount and Nature of
Beneficial
Ownership
|
%
of Class
|
Roy
T. Eddleman, Trustee, Roy T. Eddleman Trust UAD
8-7-2000
Troy
Gould PC
1801
Century Park East Suite 1600
Los
Angeles, CA 900067
|
1,495,686(1)
|
42.2%
|
|
|
|
Christopher
Cox
One
World Financial Center
New
York, NY 10281
|
444,000(2)
|
14.4%
|
|
|
|
Lyon
Polk
1585 Broadway 22nd
Floor
New
York, NY 10036
|
444,000(3)
|
14.4%
|
|
|
|
Joseph
G. Cremonese
|
136,062(4)
|
4.7%
|
|
|
|
Marcus
Frampton
|
81,812(5)
|
2.9%
|
|
|
|
John
A. Moore
|
34,786(6)
|
1.2%
|
|
|
|
Helena
R. Santos
|
38,252(7)
|
1.3%
|
|
|
|
John
F. F. Watkins
|
0
|
(*)
|
|
|
|
Karl
D. Nowosielski
|
34,183(8)
|
1.2%
|
|
|
|
Anthony
J. Mitri
|
10,000(9)
|
(*)
|
|
|
|
Robert
P. Nichols
|
27,085(10)
|
1.0%
|
|
|
|
All
directors and executive officers as a group (8
persons)
|
362,180(11)
|
12.2%
|
(1) Based upon form Schedule
13D filed with the Securities and Exchange Commission
(“SEC”) on June 24, 2020. Includes 683,850 shares
issuable upon exercise of warrants.
|
(2) Based upon from Schedule 13D filed with the SEC on June
29, 2020. Includes 222,000 shares issuable upon exercise of
warrants.
|
(3) Based upon form Schedule 13G filed with the SEC on July
9, 2020. Includes 222,000 shares issuable upon exercise of
warrants.
|
(4) 126,262 shares are owned
jointly with his wife, 7,000 shares are owned by his wife, and
5,000 shares are issuable upon exercise of
options.
|
(5) 2,250 shares are owned by Mr. Frampton. Mr. Frampton has
voting power over 77,085 shares.
|
(6) Includes 12,586 shares
issuable upon exercise of options.
|
(7) Includes 17,000 shares
issuable upon exercise of options.
|
(8) Includes 9,683 stock issued
in connection with the acquisition of the Torbal Division in
February 2014.
|
(9) Represents shares issuable upon exercise of
options.
|
(10) Includes 7,500 shares
issuable upon exercise of options.
|
(11) Includes 96,586 shares issuable upon exercise of
options.
|
|
(*) - %
of Class is less than 1%.
|
Plan
Category
|
Number
of
Securities
to
be Issued Upon Exercise
of
Outstanding Options, Warrants and Rights
(a)
|
Weighted-Average
Exercise
Price
of
Outstanding
Options, Warrants
and
Rights
($)
(b)
|
Number of Securities Remaining Available for
Future Issuance Under Equity Compensation Plans (Excluding
Securities Reflected in
Column
(a)
(c)
|
Equity
Compensation plans
approved
by security holders
|
96,600
|
4.35
|
147,400
|
Equity
Compensation plans
not
approved by security holders
|
N/A
|
N/A
|
N/A
|
Total
|
96,600
|
4.35
|
147,400
|
Exhibit
Number
|
Exhibit
|
|
|
3
|
Articles
of Incorporation and By-Laws:
|
|
|
3(a)
|
Certificate
of Incorporation of the Company as amended (filed as Exhibit 1(a-1)
to the Company's General Form for Registration of Securities on
Form 10 dated February 14, 1973 and incorporated by reference
thereto.)
|
|
|
3(b)
|
Certificate
of Amendment of the Company’s Certificate of Incorporation,
as filed on January 28, 1985 (filed as Exhibit 3(a) to the
Company’s Annual Report on Form 10-K for the fiscal year
ended June 30, 1985 and incorporated by reference
thereto.)
|
|
|
By-Laws
of the Company, as restated and amended (filed as Exhibit 3(ii) to
the Company’s Current Report on Form 8-K filed on January 6,
2003 and Exhibit 3(ii) to the Company’s Current Report on
Form 8-K filed on December 5, 2007 and incorporated by reference
thereto).
|
|
|
|
Second
Amended and Restated By-Laws of Scientific Industries, Inc. (filed
as Exhibit 3.2 to the Company’s Current Report on Form 8-K
filed on August 10, 2020 and incorporated by reference
thereto).
|
|
|
|
4
|
Instruments
defining the rights of security holders:
|
|
|
2002
Stock Option Plan (filed as Exhibit 99-1 to the Company’s
Current Report on Form 8-K filed on November 25, 2002 and
incorporated by reference thereto).
|
|
|
|
2012
Stock Option Plan (filed as Exhibit 10 to the Company’s
Current Report on Form 8-K filed on January 23, 2012 and
incorporated by reference thereto).
|
|
|
|
|
Amendment
to the Company’s 2012 Stock Option Plan (Filed as Exhibit
4(c) to the Company’s Quarterly Report on Form 10-Q filed on
May 12, 2016 and incorporated by reference thereto).
4(d)
Form of Warrant issued by the Company to Investors (Filed as
Exhibit 4.1 to the Company’s Current Report on Form 8-K filed
on June 19, 2020, and incorporated by reference
thereto).
|
|
|
10
|
Material
Contracts:
|
|
|
|
Lease
between Registrant and AIP Associates, predecessor-in-interest of
current lessor, dated October, 1989 with respect to Company's
offices and facilities in Bohemia, New York (filed as Exhibit 10(a)
to the Company’s Annual Report on Form 10-KSB filed on
September 28, 2005 and incorporated by reference
thereto).
|
|
|
|
Amendment
to lease between Registrant and REP A10 LLC, successor in interest
of AIP Associates, dated September 1, 2004 (filed as Exhibit 10A-1
to the Company’s Current Report on Form 8-K filed on
September 2, 2004, and incorporated by reference
thereto).
|
|
|
|
Second
amendment to lease between Registrant and REP A10 LLC dated
November 5, 2007 (filed as Exhibit 10A-1 to the Company’s
Current Report on Form 8-K filed on November 8, 2007, and
incorporated by reference thereto).
|
|
|
Lease
agreement dated August 8, 2014 by and between the Company and 80
Orville Drive Associates LLC.
|
|
|
|
|
Employment
Agreement dated January 1, 2003, by and between the Company and Ms.
Santos (filed as Exhibit 10(a) to the Company’s Current
Report on Form 8-K filed on January 22, 2003, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated September 1, 2004, by and between the Company and
Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on September 1, 2004, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated December 29, 2006, by and between the Company and
Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on December 29, 2006, and incorporated by
reference thereto).
|
|
Employment
Agreement dated July 31, 2009 by and between the Company and Ms.
Santos (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on August 7, 2009, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated May 14, 2010 by and between the Company and Ms.
Santos (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on May 18, 2010, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated September 13, 2011 by and between the Company and
Ms. Santos (filed as exhibit 10(b)-5 to the Company’s Annual
Report on Form 10-K for the fiscal year ended June 30, 2011, and
incorporated by reference thereto).
|
|
|
|
Amended
Employment Agreement dated May 20, 2013 by and between the Company
and Ms. Santos (filed as Exhibit 10A-1 to the Company’s
Current Report on Form 8-K filed on May 20, 2013, and incorporated
by reference thereto).
|
|
|
|
Agreement
extension dated June 9, 2015 to amend employment agreement by and
between the Company and Ms. Santos (filed as Exhibit 10A-1 to the
Company’s Current Report on Form 8-K filed on June 9, 2015,
and incorporated by reference thereto)
|
|
|
|
Agreement
extension dated May 25, 2016 to amend employment agreement by and
between the Company and Ms. Santos (filed as Exhibit 10A-1 to the
Company’s Current Report on Form 8-K filed on May 31, 2016,
and incorporated by reference thereto).
|
|
|
|
Employment
agreement dated July 1, 2017 by and between the Company and Ms.
Santos (filed as an exhibit to the Company's Annual Report on Form
10-K for the fiscal year ended June 30, 2017, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated January 1, 2003, by and between the Company and Mr.
Robert P. Nichols (filed as Exhibit 10A-1 to the Company’s
Current Report on Form 8-K filed on January 22, 2003, and
incorporated by reference thereto).
|
|
|
|
Employment
Agreement dated September 1, 2004, by and between the Company and
Mr. Nichols (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on September 1, 2004, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated December 29, 2006, by and between the Company and
Mr. Nichols (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on December 29, 2006, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated July 31, 2009 by and between the Company and Mr.
Nichols (filed as Exhibit 10A-2 to the Company’s Current
Report on Form 8-K filed on August 7, 2009, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated May 14, 2010 by and between the Company and Mr.
Nichols (filed as Exhibit 10A-2 to the Company’s Current
Report on Form 8-K filed on May 18, 2010, and incorporated by
reference thereto).
|
|
|
|
Employment
Agreement dated September 13, 2011 by and between the Company and
Mr. Nichols (filed as Exhibit 10(c)-5 to the Company’s Annual
Report on Form 10-K for the fiscal year ended June 30, 2011, and
incorporated by reference thereto).
|
|
|
|
Amended
Employment Agreement dated May 20, 2013 by and between the Company
and Mr. Nichols (filed as Exhibit 10A-2 to the Company’s
current Report on Form 8-K filed on May 20, 2013, and incorporated
by reference thereto).
|
|
|
|
Agreement
extension dated June 9, 2015 to amend employment agreement with Mr.
Nichols (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on June 9, 2015, and incorporated by
reference thereto).
|
|
|
|
Agreement
e Agreement extension dated May 25, 2016 to amend employment
agreement with Mr. Nichols (filed as Exhibit 10A-1 to the
Company’s Current Report on Form 8-K filed on May 31, 2016,
and incorporated by reference thereto).
|
|
|
|
Employment
agreement dated July 1, 2017 by and between the Company and Mr.
Nichols (filed as an exhibit to the Company's Annual Report on Form
10-K for the fiscal year ended June 30, 2017, and incorporated by
reference thereto).
|
|
|
|
Consulting
Agreement dated January 1, 2003 by and between the Company and Mr.
Cremonese and his affiliate, Laboratory Innovation Company, Ltd.
(filed as Exhibit 10(b) to the Company’s Current Report on
Form 8-K filed on January 6, 2003, and incorporated by reference
thereto).
|
|
|
|
Amended
and Restated Consulting Agreement dated March 22, 2005, by and
between the Company and Mr. Cremonese and Laboratory Innovation
Company, Ltd. (filed as Exhibit 10A-1 to the Company’s
Current Report on Form 8-K filed on March 23, 2005, and
incorporated by reference thereto).
|
|
|
|
Second
Amended and Restated Consulting Agreement dated March 15, 2007, by
and between the Company and Mr. Cremonese and Laboratory Innovation
Company Ltd. (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on March 16, 2007, and incorporated by
reference thereto).
|
|
|
|
Third
Amended and Restated Consulting Agreement dated September 23, 2009,
by and between the Company and Mr. Cremonese and Laboratory
Innovation Company, Ltd. (filed as Exhibit 10 to the
Company’s Annual Report on Form 10-K field on September 24,
2009, and incorporated by reference thereto).
|
|
|
|
Fourth
Amended and Restated Consulting Agreement dated January 7, 2011
(filed as Exhibit 10A-1 to the Company’s Current Report on
Form 8-K (filed on January 18, 2011, and incorporated by reference
thereto).
|
|
Fifth
Amendment and Restated Consulting Agreement dated January 20, 2012
(filed as Exhibit 10 to the Company’s Current Report on Form
8-K (filed on January 23, 2012, and incorporated by reference
thereto).
|
|
|
|
|
|
Agreement
extension dated November 29, 2012 to Amended and Restated
Consulting Agreement (filed as Exhibit 10 to the Company’s
Current Report on Form 8-K filed on December 4, 2012, and
incorporated by reference thereto).
|
|
|
|
|
|
Agreement
extension dated December 12, 2013 to Amended and Restated
Consulting Agreement (filed as Exhibit 10 to the Company’s
Current Report on Form 8-K filed on December 12, 2013, and
incorporated by reference thereto).
|
|
|
|
|
|
Agreement
extension dated January 14, 2015 to Amended and Restated Consulting
Agreement by and between the Company and Mr. Cremonese and
affiliates (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on January 15, 2015, and incorporated with
reference thereto).
|
|
|
|
|
|
Agreement
extension dated January 7, 2016 to Amended and Restated Consulting
Agreement by and between the Company and Mr. Cremonese and
affiliates (filed as Exhibit 10A-1 to the Company’s Current
Report on Form 8-K filed on January 26, 2016, and incorporated with
reference thereto).
|
|
|
|
|
|
Agreement
extension dated February 16, 2018 to Amended and Restated
Consulting Agreement by and between the Company and Mr. Cremonese
and affiliates (filed as Exhibit 10-A1 to the Company’s
Current Report on Form 8-K filed on March 9, 2018, and incorporated
with reference thereto).
|
|
|
|
|
|
Agreement
extension dated January 23, 2019 to Amended and Restated Consulting
Agreement by and between the Company and Mr. Cremonese and
affiliates (filed as Exhibit 10-1 to the Company’s Current
Report on Form 8-K filed on January 25, 2019, and incorporated with
reference thereto).
|
|
|
||
10(d)-12
|
Monthly
Retainer Agreement between Scientific Bioprocessing, Inc. and Mr.
Cremonese and affiliates (filed as Exhibit 10(d)-12 to the
Company’s Quarterly Report on Form 10-Q on February 13, 2020,
and incorporated by reference thereto).
|
|
|
||
Sublicense
from Fluorometrix Corporation (filed as Exhibit 10(a)1 to the
Company’s Current Report on Form 8-K filed on June 14, 2006,
and incorporated by reference thereto).
|
||
|
|
|
|
Stock
Purchase Agreement, dated as of November 30, 2006, by and among the
Company and Grace Morin, Heather H. Haught and William D. Chandler
(filed as Exhibit 2.1 to the Company’s Current Report on Form
8-K filed on December 5, 2006, and incorporated by reference
thereto).
|
|
|
|
|
|
Escrow
Agreement, dated as of November 30, 2006, by and among the Company
and Grace Morin, Heather H. Haught and William D. Chandler (filed
as Exhibit 10(a) to the Company’s Current Report on Form 8-K
filed on December 5, 2006, and incorporated by reference
thereto).
|
|
Registration
Rights Agreement, dated as of November 30, 2006, by and among the
Company and Grace Morin, Heather H. Haught and William D. Chandler
(filed as Exhibit 10(b) to the Company’s Current Report on
Form 8-K filed on December 5, 2006, and incorporated by reference
thereto).
|
|
|
|
|
|
Employment
Agreement, dated as of November 30, 2006, between Altamira
Instruments, Inc. and Brookman P. March (filed as Exhibit 10(c) to
the Company’s Current Report on Form 8-K filed on December 5,
2006, and incorporated by reference thereto).
|
|
|
|
|
|
Employment
Agreement, dated as of October 30, 2008, between Altamira
Instruments, Inc. and Brookman P. March (filed as Exhibit 10A-2 to
the Company’s Current Report on Form 8-K filed on October 30,
2008, and incorporated by reference thereto).
|
|
|
|
|
|
Employment
Agreement, dated as of October 1, 2010, between Altamira
Instruments, Inc., and Brookman P. March (filed as Exhibit 10A-1 to
the Company’s Current Report on Form 8-K filed on October 13,
2010, and incorporated by reference thereto).
|
|
|
|
|
|
Employment
Agreement, dated as of May 18, 2012 between Altamira Instruments,
Inc. and Brookman P. March (filed as Exhibit 10(i)-3 to the
Company’s Annual Report on Form 10-K filed on September 27,
2012, and incorporated by reference thereto).
|
|
|
|
|
|
Agreement
Extension, dated as of May 21, 2014 between Altamira Instruments,
Inc. and Brookman P. March (filed as Exhibit 10 to the
Company’s Current Report on Form 8-K filed on May 21, 2014,
and incorporated by reference thereto).
|
|
|
|
|
Agreement
extension dated June 9, 2015 to amend employment agreement (filed
as Exhibit 10A-1 to the Company’s Current Report on Form 8-K
filed on June 9, 2015, and incorporated by reference
thereto).
|
||
|
|
|
Agreement
extension dated May 25, 2016 to amend employment agreement (filed
as Exhibit 10A-1 to the Company’s Current Report on Form 8-K
filed on May 31, 2016, and incorporated by reference
thereto).
|
||
|
|
|
Employment
agreement dated July 1, 2017 by and between the Company and Mr.
March (filed as an exhibit to the Company's Annual Report on Form
10-K filed on June 30, 2017, and incorporated by reference
thereto).
|
||
|
||
10(i)-8
|
Termination notice
dated February 14, 2020 to Mr. March (filed as Exhibit 10(I-8) to
the Company’s Current Report on Form 8-K filed on February
18, 2020, and incorporated by reference thereto).
|
|
|
|
|
Indemnity
Agreement, dated as of April 13, 2007 by and among the Company and
Grace Morin, Heather H. Haught and William D. Chandler (filed as
Exhibit 10(j) to the Company’s Annual Report on Form 10-KSB
filed on September 28, 2007 and incorporated by reference
thereto).
|
||
|
|
|
Lease
between Altamira Instruments, Inc. and Allegheny Homes, LLC, with
respect to the Company’s Pittsburgh, Pennsylvania facilities
(filed as Exhibit 10(k) to the Company’s Annual Report on
Form 10-KSB filed on September 28, 2007 and incorporated by
reference thereto).
|
Lease
between Altamira Instruments, Inc. and Allegheny Homes, LLC, with
respect to the Company’s Pittsburgh, Pennsylvania facilities
(filed as Exhibit 10(k)-1 to the Company’s Quarterly Report
on Form 10-Q filed on February 14, 2013, and incorporated by
reference thereto).
|
|
|
|
Line
of Credit Agreements dated October 30, 2008, by and among the
Company and Capital One, N.A. (filed as Exhibits 10-A1(a) through
(f) to the Company’s Current Report on Form 8-K filed on
October 30, 2008, and incorporated by reference
thereto.
|
|
|
|
Restated
Promissory Note Agreement dated January 20, 2010 by and among the
Company and Capital One N.A. (filed as Exhibit 99.1 to the
Company’s Current Report on Form 8-K filed on January 20,
2010, and incorporated by reference thereto).
|
|
|
|
Consulting
Agreement dated April 1, 2009 by and between the Company and Grace
Morin (filed as Exhibit 10A-1 to the Company’s Current Report
on Form 8-K filed on April 1, 2009, and incorporated by reference
thereto).
|
|
|
|
Agreement
dated January 12, 2015 to extend Consulting Agreement (filed as
Exhibit 10A-2 to the Company’s Current Report on Form 8-K
filed on January 15, 2015, and incorporated by reference
thereto).
|
|
|
|
Agreement
dated January 7, 2016 to extend Consulting Agreement (filed as
Exhibit 10A-2 to the Company’s Current Report on Form 8-K
filed on January 26, 2016, and incorporated by reference
thereto).
|
|
|
|
Agreement
dated February 16, 2018 to extend Consulting Agreement (filed as
Exhibit 10A-2 to the Company’s Current Report on Form 8-K
filed on March 9, 2018, and incorporated by reference
thereto).
|
|
|
|
Agreement
dated January 23, 2019 to extend Consulting Agreement (filed as
Exhibit 10-2 to the Company’s Current Report on Form 8-K
filed on January 25, 2019, and incorporated by reference
thereto).
|
|
|
|
Line
of Credit Agreements dated June 14, 2011, by and among the Company
and JPMorgan Chase Bank, N.A. (filed as Exhibits 99.1 through 99.3
to the Company’s Current Report on Form 8-K filed on June 16,
2011, and incorporated by reference thereto).
|
|
|
|
Promissory
Note dated June 5, 2013 by and among the Company and JP Morgan
Chase Bank, N.A. (filed as Exhibit 99 to the Company’s
Current Report on Form 8-K filed on June 7, 2013, and incorporated
by reference thereto).
|
|
|
|
Purchase
Agreement, dated as of November 14, 2011, by and among the Company,
Scientific Bioprocessing, Inc., and Fluorometrix Corporation (filed
as Exhibit 2.1 to the Company’s Current Report on Form 8-K
filed on November 17, 2011, and incorporated by reference
thereto).
|
|
|
|
Escrow
Agreement, dated as of November 14, 2011, by and among the Company,
Scientific Bioprocessing, Inc., and Fluorometrix Corporation (filed
as Exhibit 10(A) to the Company’s Current Report on Form 8-K
filed on November 17, 2011, and incorporated by reference
thereto).
|
|
|
|
Research
and Development Agreement dated as of November 14, 2011, by and
between Scientific Bioprocessing, Inc. and Biodox R&D
Corporation (filed as Exhibit 10(B) to the Company’s Current
Report on Form 8-K filed on November 17, 2011, and incorporated by
reference thereto).
|
|
|
Notice
of termination of Research and Development Agreement dated June 12,
2013 (filed as Exhibit 99 to the Company’s Current Report on
Form 8-K filed on June 27, 2013, and incorporated by reference
thereto)
|
|
|
|
Non-Competition
Agreement, dated as of November 14, 2011, by and among the Company,
Scientific Bioprocessing, Inc., and Joseph E. Qualitz (filed as
Exhibit 10(D) to the Company’s Current Report on Form 8-K
filed on November 17, 2011, and incorporated by reference
thereto).
|
|
|
|
Promissory
Note, dated as of November 14, 2011, by and between the Company and
the University of Maryland, Baltimore County (filed as Exhibit
10(c) to the Company’s Current Report on Form 8-K filed on
November 17, 2011, and incorporated by reference
thereto).
|
|
|
|
License
Agreement, dated as of January 31, 2001 by and between University
of Maryland, Baltimore County and Fluorometrix Corporation (filed
as Exhibit 10(E) to the Company’s Current Report on Form 8-K
filed on November 21, 2011, and incorporated by reference
thereto).
|
|
|
|
Line
of Credit Agreements dated June 25, 2014, by and among the Company
and Bank of America Merrill Lynch (filed as Exhibits 99.1 through
99.2 (to the Company’s Current Report on Form 8-K filed on
July 2, 2014, and incorporated by reference thereto).
|
|
|
|
Asset
Purchase Agreement, dated as of February 26, 2014, by and among the
Company and Fulcrum, Inc. (filed as Exhibit 2.1 to the
Company’s Current Report on Form 8-K filed on February 28,
2014, and incorporated by reference thereto).
|
|
|
|
Escrow
Agreement, dated as of February 26, 2014, by and among the Company,
and Fulcrum, Inc. (filed as Exhibit 10(e) to the Company’s
Current Report on Form 8-K filed on February 28, 2014, and
incorporated by reference thereto).
|
|
|
|
Non-Competition
Agreements, dated as of February 26, 2014, by and among the
Company, and James Maloy and Karl Nowosielski (filed as Exhibits
10(b) and 10(c) to the Company’s Current Report on Form 8-K
filed on February 28, 2014, and incorporated by reference
thereto).
|
|
|
|
Registration Rights Agreement,
dated as of February 26, 2014, by and among the Company, and
Fulcrum, Inc. (filed as Exhibit 10(d) to the Company’s
Current Report on Form 8-K filed on February 28, 2014, and
incorporated by reference thereto).
|
Supply
Agreement, dated as of February 20, 2014, by and among the Company,
and Axis Sp 3.O.O. (filed as Exhibit 10(g) to the Company’s
Current Report on Form 8-K filed on February 28, 2014, and
incorporated by reference thereto).
|
|
|
|
Line
of Credit Agreements dated June 26, 2015, by and among the Company
and First National Bank of Pennsylvania (filed as Exhibit 10.1
through 10.4 to the Company’s Current Report on Form 8-K
filed on June 30, 2015, and incorporated by reference
thereto).
|
|
|
|
Commercial
Security Agreement dated July 5, 2016 by and among the Company, and
First National Bank of Pennsylvania.
|
|
|
|
Note
Purchase Agreements with James Maloy dated May 7, 2015 (filed as
Exhibit 10.6 to the Company’s Current Report on Form 8-K
filed on June 30, 2015, and incorporated by reference
thereto).
|
|
|
|
Note
Purchase Agreements with Grace March dated May 19, 2015 (filed as
Exhibit 10.6 to the Company’s Current Report on Form 8-K
filed on June 30, 2015, and incorporated by reference
thereto).
|
|
|
|
|
Consulting
Agreement dated March 1, 2019 between the Company and Mr. John A.
Moore (filed as Exhibit 10A-1 to the Company’s Current Report
on Form 8-K filed on March 6, 2019, and incorporated by reference
thereto).
|
|
|
10(aa)-1 | Amendment to Consulting Agreement dated November 7, 2019 between the Company and Mr. John A. Moore (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 11, 2019, and incorporated by reference thereto). |
|
|
10(aa)-2 |
Employment
Agreement dated July 1, 2020 between Scientific Bioprocessing, Inc.
and John A. Moore (filed as Exhibit 10.1 to the Company’s
Current Report on Form 8-K filed on June 25, 2020, and incorporated
by reference thereto).
|
|
|
|
Consulting
Agreement dated July 20, 2020 between the Company and Mr. Reinhard
Vogt and his affiliate Societat Reinhard and Noah Vogt AG (filed as
Exhibit 10A-1 to the Company’s Current Report on Form 8-K
filed on July 22, 2020, and incorporated by reference
thereto.)
|
|
|
10(cc)
|
Employment
Agreement dated July 1, 2020 between Scientific Bioprocessing, Inc.
and James Polk (filed as Exhibit 10.2 to the Company’s
Current Report on Form 8-K filed on June 25, 2020, and incorporated
by reference thereto).
|
|
|
10(dd)
|
Securities
Purchase Agreement dated June 18, 2020 between the Company and
Investors (filed as Exhibit 10.1 to the Company’s Current
Report on Form 8-K filed on June 19, 2020, and incorporated by
reference thereto).
|
|
|
10(ee)
|
Loan
Agreement under the U.S. Small Business Administration Paycheck
Protection Program dated April 14, 2020 between the Company and
First National Bank (filed as Exhibit 10.1 to the Company’s
Current Report on Form 8-K filed on April 21, 2020, and
incorporated by reference thereto).
|
|
|
Code
of Ethics (filed as Exhibit 14 to the Company’s Annual 10KSB
filed on September 28, 2007 and incorporated by reference
thereto).
|
|
|
|
21
|
Subsidiaries
of the Registrant
|
|
|
|
Altamira
Instruments, Inc., a Delaware Corporation, is a wholly-owned
subsidiary of the Company.
|
|
|
|
Scientific
Bioprocessing, Inc., a Delaware Corporation, is a wholly-owned
subsidiary of the Company since November 2011.
|
|
|
|
Scientific
Packaging Industries, Inc., a New York corporation, is a
wholly-owned inactive subsidiary of the Company.
|
|
|
31.01
|
Certification
of Chief Executive Officer and Chief Financial Officer pursuant to
Section 302 of Sarbanes-Oxley Act of 2002.
|
|
|
32.01
|
Certification
of Chief Executive Officer and Chief Financial Officer pursuant to
Section 906 of Sarbanes-Oxley Act of 2002.
|
Date: October 09, 2020
|
SCIENTIFIC INDUSTRIES, INC.
(Registrant)
/s/Helena
R. Santos
|
|
Helena R. Santos
President, Chief Executive Officer,
Chief Financial Officer and Treasurer
|
Name
|
Title
|
Date
|
|
|
|
|
|
|
Helena R. Santos
|
President, Chief Executive Officer, Chief Financial Officer and
Treasurer
|
October 09, 2020
|
|
|
|
Joseph G. Cremonese
|
Director
|
October 09, 2020
|
|
|
|
Marcus Frampton
|
Director
|
October 09, 2020
|
|
|
|
John A. Moore
|
Chairman of the Board
|
October 09, 2020
|
|
|
|
Reinhard Vogt
|
Director
|
October 09, 2020
|
|
|
|
John
F.F. Watkins
|
Director
|
October
09, 2020
|
|
|
|
|
Page
|
|
|
Report
of independent registered public accounting firm
|
F-1
|
|
|
Consolidated
financial statements:
|
|
|
|
Balance
sheets
|
F-2
|
|
|
Statements of
operations
|
F-3
|
|
|
Statements of
changes in stockholders’ equity
|
F-4
|
|
|
Statements of cash
flows
|
F-5
|
|
|
Notes
to financial statements
|
F-6
– F-25
|
|
2020
|
2019
|
Current
assets:
|
|
|
Cash and cash
equivalents
|
$7,559,700
|
$1,602,500
|
Investment
securities
|
331,800
|
330,900
|
Trade accounts
receivable, less allowance for doubtful accounts of $11,600 and
$15,000, respectively
|
1,064,000
|
1,974,200
|
Inventories
|
2,884,700
|
2,592,300
|
Income tax
receivable
|
334,800
|
-
|
Prepaid expenses
and other current assets
|
112,300
|
91,200
|
|
|
|
Total current
assets
|
12,287,300
|
6,591,100
|
|
|
|
Property and
equipment, net
|
279,700
|
318,800
|
|
|
|
Intangible assets,
net
|
128,700
|
175,000
|
|
|
|
Goodwill
|
705,300
|
705,300
|
|
|
|
Operating lease
right-of-use assets
|
803,300
|
-
|
|
|
|
Other
assets
|
56,000
|
54,700
|
|
|
|
Deferred
taxes
|
537,100
|
431,100
|
|
|
|
Total
assets
|
$14,797,400
|
$8,276,000
|
Current
liabilities:
|
|
|
Accounts
payable
|
$354,700
|
$569,000
|
Accrued expenses
and taxes
|
799,700
|
608,300
|
Contract
liabilities
|
89,000
|
-
|
Contingent
consideration, current portion
|
111,000
|
268,000
|
Bank
overdraft
|
43,100
|
140,000
|
Lease liabilities,
current portion
|
226,900
|
-
|
Payroll Protection
Program loan
|
563,800
|
-
|
|
|
|
Total current
liabilities
|
2,188,200
|
1,585,300
|
|
|
|
Lease liabilities,
less current portion
|
640,800
|
-
|
Contingent
consideration payable, less current portion
|
247,000
|
350,000
|
|
|
|
Total
liabilities
|
3,076,000
|
1,935,300
|
|
|
|
Stockholders’
equity:
|
|
|
Common stock, $.05 par value;
7,000,000 shares authorized; 2,881,065 and 1,513,914 shares issued; 2,861,263
and 1,494,112 shares outstanding in 2020 and 2019,
respectively
|
144,100
|
75,700
|
Additional paid-in
capital
|
8,608,300
|
2,592,700
|
Retained
earnings
|
3,021,400
|
3,724,700
|
|
11,773,800
|
6,393,100
|
Less common stock
held in treasury at cost, 19,802 shares
|
52,400
|
52,400
|
|
|
|
Total
stockholders’ equity
|
11,721,400
|
6,340,700
|
|
|
|
Total liabilities
and stockholders’ equity
|
$14,797,400
|
$8,276,000
|
|
2020
|
2019
|
|
|
|
Revenues
|
$8,570,300
|
$10,199,800
|
|
|
|
Cost of
revenues
|
4,716,900
|
5,832,700
|
|
|
|
Gross
profit
|
3,853,400
|
4,367,100
|
|
|
|
Operating
expenses:
|
|
|
General and
administrative
|
2,412,300
|
1,924,400
|
Selling
|
1,436,400
|
1,136,100
|
Research and
development
|
1,140,000
|
530,500
|
|
|
|
Total operating
expenses
|
4,988,700
|
3,591,000
|
|
|
|
Income (loss) from
operations
|
(1,136,300)
|
776,100
|
|
|
|
Other income
(expense):
|
|
|
Interest
income
|
12,600
|
3,400
|
Other income
(expense), net
|
(16,200)
|
(7,800)
|
Interest
expense
|
-
|
(1,500)
|
|
|
|
Total other income
(expense), net
|
(3,600)
|
(5,900)
|
|
|
|
Income (loss)
before income tax expense (benefit)
|
(1,139,900)
|
770,200
|
|
|
|
Income tax expense
(benefit):
|
|
|
Current
|
-
|
166,600
|
Deferred
|
(436,600)
|
(42,000)
|
|
|
|
Total income tax
expense (benefit)
|
(436,600)
|
124,600
|
|
|
|
Net income
(loss)
|
$(703,300)
|
$645,600
|
|
|
|
Basic earnings
(loss) per common share
|
$(.46)
|
$.43
|
|
|
|
Diluted earnings
(loss) per common share
|
$(.46)
|
$.43
|
|
|
|
Weighted average
common shares, basic
|
1,515,103
|
1,494,112
|
|
|
|
Weighted average
common shares outstanding, assuming dilution (in 2019)
|
1,515,103
|
1,512,178
|
|
|
Additional
|
Accumulated
Other
|
|
|
Total
|
||
|
Common
Stock
|
Paid-in
|
Comprehensive
|
Retained
|
Treasury
Stock
|
Stockholders’
|
||
|
Shares
|
Amount
|
Capital
|
Income
(Loss)
|
Earnings
|
Shares
|
Amount
|
Equity
|
|
|
|
|
|
|
|
|
|
Balance, July 1,
2018
|
1,513,914
|
$75,700
|
$2,545,900
|
$1,200
|
$3,131,800
|
19,802
|
$52,400
|
$5,702,200
|
|
|
|
|
|
|
|
|
|
Cumulative effect
of the adoption of Accounting Standards Update
(“ASU”) 2016-01 - Financial
Instruments
|
-
|
-
|
-
|
(22,000)
|
22,000
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
Net
income
|
-
|
-
|
-
|
-
|
645,600
|
-
|
-
|
645,600
|
|
|
|
|
|
|
|
|
|
Cash dividend
declared and paid, $.05
|
-
|
-
|
-
|
-
|
(74,700)
|
-
|
-
|
(74,700)
|
|
|
|
|
|
|
|
|
|
Holding loss on
investment securities, net of tax
|
-
|
-
|
-
|
20,800
|
-
|
-
|
-
|
20,800
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation
|
-
|
-
|
46,800
|
-
|
-
|
-
|
-
|
46,800
|
|
|
|
|
|
|
|
|
|
Balance, June 30,
2019
|
1,513,914
|
75,700
|
2,592,700
|
-
|
3,724,700
|
19,802
|
52,400
|
6,340,700
|
|
|
|
|
|
|
|
|
|
Net
loss
|
-
|
-
|
-
|
-
|
(703,300)
|
-
|
-
|
(703,300)
|
|
|
|
|
|
|
|
|
|
Issuance of Common
Stock and Warrants, net of issuance costs (Note 15)
|
1,349,850
|
67,500
|
5,936,900
|
-
|
-
|
-
|
-
|
6,004,400
|
|
|
|
|
|
|
|
|
|
Stock options
exercised
|
17,301
|
900
|
12,900
|
-
|
-
|
-
|
-
|
13,800
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation
|
-
|
-
|
65,800
|
-
|
-
|
-
|
-
|
65,800
|
|
|
|
|
|
|
|
|
|
Balance, June 30,
2020
|
2,881,065
|
$144,100
|
$8,608,300
|
$-
|
$3,021,400
|
19,802
|
$52,400
|
$11,721,400
|
|
2020
|
2019
|
Operating
activities:
|
|
|
Net income
(loss)
|
$(703,300)
|
$645,600
|
Adjustments to
reconcile net income (loss) to net cash provided by
(used in) operating
activities:
|
|
|
(Gain) loss on sale
of investment securities
|
(4,400)
|
13,200
|
Depreciation and
amortization
|
160,900
|
257,300
|
Deferred income tax
(benefit) expense
|
(106,000)
|
(38,500)
|
Unrealized holding
(gain) loss on investment securities
|
12,400
|
(3,000)
|
Bad debt
recovery
|
3,400
|
-
|
Gain on sale of
fixed assets
|
(300)
|
-
|
Stock-based
compensation
|
65,800
|
46,800
|
Change in fair
value of contingent consideration
|
112,600
|
521,200
|
Changes in
operating assets and liabilities:
|
|
|
Trade accounts
receivable
|
906,800
|
(6,500)
|
Inventories
|
(292,400)
|
(324,400)
|
Income tax
receivable
|
(334,800)
|
-
|
Prepaid expenses
and other assets
|
(22,400)
|
(60,100)
|
Right-of-use
assets
|
(803,300)
|
-
|
Accounts
payable
|
(214,400)
|
141,000
|
Lease
liabilities
|
867,700
|
-
|
Accrued expenses
and taxes
|
191,500
|
(109,300)
|
Contract
liabilities
|
89,000
|
(63,800)
|
Bank
overdraft
|
(96,900)
|
140,000
|
|
|
|
Total
adjustments
|
535,200
|
513,900
|
|
|
|
Net cash (used in)
provided by operating activities
|
(168,100)
|
1,159,500
|
|
|
|
Investing
activities:
|
|
|
Purchase of
investment securities
|
(63,400)
|
(157,900)
|
Redemption of
investment securities
|
55,000
|
151,900
|
Proceeds from sale
of fixed assets
|
1,000
|
-
|
Capital
expenditures
|
(50,900)
|
(187,800)
|
Purchase of
intangible assets
|
(25,800)
|
(24,600)
|
|
|
|
Net cash used in
investing activities
|
(84,100)
|
(218,400)
|
|
|
|
Financing
activities:
|
|
|
Principal payments
on notes payable
|
-
|
(5,800)
|
Cash dividend
declared and paid
|
-
|
(74,700)
|
Proceeds from
Payroll Protection Program loan
|
563,800
|
-
|
Line of credit
proceeds
|
-
|
50,000
|
Issuance of common
stock and warrants, net of issuance costs
|
6,004,400
|
-
|
Line of credit
repayments
|
-
|
(50,000)
|
Proceeds from
exercise of stock options
|
13,800
|
-
|
Payments for
contingent consideration
|
(372,600)
|
(311,200)
|
|
|
|
Net cash provided
by (used in) financing activities
|
6,209,400
|
(391,700)
|
|
|
|
Net increase in
cash and cash equivalents
|
5,957,200
|
549,400
|
|
|
|
Cash and cash
equivalents, beginning of year
|
1,602,500
|
1,053,100
|
|
|
|
Cash and cash
equivalents, end of year
|
$7,559,700
|
$1,602,500
|
|
|
|
Supplemental
disclosures:
|
|
|
Cash paid during
the period for:
|
|
|
Income
taxes
|
$40,900
|
$56,700
|
Interest
|
$-
|
$1,500
|
|
Benchtop
Laboratory
Equipment
|
Catalyst
Research
Instruments
|
Bioprocessing
Systems
|
Corporate
and
Other
|
Consolidated
|
June 30,
2020:
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
$6,783,600
|
$785,900
|
$1,000,800
|
$-
|
$8,570,300
|
|
|
|
|
|
|
Foreign
Sales
|
2,589,800
|
586,500
|
1,000,400
|
-
|
4,176,700
|
|
Benchtop
Laboratory
Equipment
|
Catalyst
Research
Instruments
|
Bioprocessing
Systems
|
Corporate
and
Other
|
Consolidated
|
June 30,
2019:
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
$7,078,800
|
$1,814,900
|
$1,306,100
|
$-
|
$10,199,800
|
|
|
|
|
|
|
Foreign
Sales
|
2,680,300
|
1,102,300
|
1,301,200
|
-
|
5,083,800
|
|
Benchtop
Laboratory
Equipment
|
Catalyst
Research
Instruments
|
Bioprocessing
Systems
|
Corporate
and
Other
|
Consolidated
|
June 30,
2020:
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
$6,783,600
|
$785,900
|
$1,000,800
|
$-
|
$8,570,300
|
|
|
|
|
|
|
Foreign
Sales
|
2,589,800
|
586,500
|
1,000,400
|
-
|
4,176,700
|
|
|
|
|
|
|
Income (Loss) From
Operations
|
449,700
|
(472,800)
|
(727,500)
|
(385,700)
|
(1,136,300)
|
|
|
|
|
|
|
Assets
|
12,232,600
|
1,149,800
|
546,100
|
868,900
|
14,797,400
|
|
|
|
|
|
|
Long-Lived Asset
Expenditures
|
36,000
|
-
|
40,700
|
-
|
76,700
|
|
|
|
|
|
|
Depreciation and
Amortization
|
116,900
|
1,300
|
42,700
|
-
|
160,900
|
|
Benchtop
Laboratory
Equipment
|
Catalyst
Research
Instruments
|
Bioprocessing
Systems
|
Corporate
and
Other
|
Consolidated
|
June 30,
2019:
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
$7,078,800
|
$1,814,900
|
$1,306,100
|
$-
|
$10,199,800
|
|
|
|
|
|
|
Foreign
Sales
|
2,680,300
|
1,102,300
|
1,301,200
|
-
|
5,083,800
|
|
|
|
|
|
|
Income (Loss) From
Operations
|
449,800
|
(130,600)
|
365,000
|
91,900
|
776,100
|
|
|
|
|
|
|
Assets
|
5,280,700
|
1,443,200
|
790,100
|
762,000
|
8,276,000
|
|
|
|
|
|
|
Long-Lived Asset
Expenditures
|
194,500
|
2,200
|
15,700
|
-
|
212,400
|
|
|
|
|
|
|
Depreciation and
Amortization
|
217,800
|
1,000
|
38,500
|
-
|
257,300
|
|
|
Fair
Value Measurements Using Inputs Considered as
|
||
|
Fair Value
at
June 30,
2020
|
Level
1
|
Level
2
|
Level
3
|
Assets:
|
|
|
|
|
Cash and cash
equivalents
|
$7,559,700
|
$7,559,700
|
$-
|
$-
|
Investment
securities
|
331,800
|
331,800
|
-
|
-
|
|
|
|
|
|
Total
|
$7,891,500
|
$7,891,500
|
$-
|
$-
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
Contingent
consideration
|
$358,000
|
$-
|
$-
|
$358,000
|
|
|
Fair
Value Measurements Using Inputs Considered as
|
||
|
Fair Value
at
June 30,
2019
|
Level
1
|
Level
2
|
Level
3
|
Assets:
|
|
|
|
|
Cash and cash
equivalents
|
$1,602,500
|
$1,602,500
|
$-
|
$-
|
Investment
securities
|
330,900
|
330,900
|
-
|
-
|
|
|
|
|
|
Total
|
$1,933,400
|
$1,933,400
|
$-
|
$-
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
Contingent
consideration
|
$618,000
|
$-
|
$-
|
$618,000
|
|
2020
|
2019
|
|
|
|
Beginning
balance
|
$618,000
|
$408,000
|
Increase in
contingent consideration liability
|
112,600
|
521,200
|
Payments and
accruals
|
(372,600)
|
(311,200)
|
|
|
|
Ending
balance
|
$358,000
|
$618,000
|
|
Cost
|
Fair
Value
|
Unrealized
Holding
Gain
(Loss)
|
At June 30,
2020:
|
|
|
|
|
|
|
|
Equity
securities
|
$77,600
|
$101,900
|
$24,300
|
Mutual
funds
|
250,300
|
229,900
|
(20,400)
|
|
|
|
|
|
$327,900
|
$331,800
|
$3,900
|
|
Cost
|
Fair
Value
|
Unrealized
Holding
Gain
(Loss)
|
At June 30,
2019:
|
|
|
|
|
|
|
|
Equity
securities
|
$47,100
|
$72,000
|
$24,900
|
Mutual
funds
|
292,300
|
258,900
|
(33,400)
|
|
|
|
|
|
$339,400
|
$330,900
|
$(8,500)
|
|
2020
|
2019
|
|
|
|
Raw
materials
|
$1,838,500
|
$1,738,300
|
Work-in-process
|
228,600
|
106,400
|
Finished
goods
|
817,600
|
747,600
|
|
|
|
|
$2,884,700
|
$2,592,300
|
|
Useful
Lives
|
|
|
|
(Years)
|
2020
|
2019
|
|
|
|
|
Automobiles
|
5
|
$22,000
|
$22,000
|
Computer
equipment
|
3-5
|
247,900
|
233,900
|
Machinery and
equipment
|
3-7
|
1,010,600
|
986,500
|
Furniture and
fixtures
|
4-10
|
209,700
|
205,900
|
Leasehold
improvements
|
3-10
|
53,300
|
45,300
|
|
|
|
|
|
|
1,543,500
|
1,493,600
|
Less accumulated
depreciation and amortization
|
|
1,263,800
|
1,174,800
|
|
|
|
|
|
|
$279,700
|
$318,800
|
|
Useful
Lives
|
Cost
|
Accumulated
Amortization
|
Net
|
At June 30,
2020:
|
|
|
|
|
|
|
|
|
|
Technology,
trademarks
|
5/10
yrs.
|
$664,700
|
$662,000
|
$2,700
|
Trade
names
|
6 yrs.
|
140,000
|
140,000
|
-
|
Websites
|
5 yrs.
|
210,000
|
210,000
|
-
|
Customer
relationships
|
9/10
yrs.
|
357,000
|
321,400
|
35,600
|
Sublicense
agreements
|
10
yrs.
|
294,000
|
253,600
|
40,400
|
Non-compete
agreements
|
5 yrs.
|
384,000
|
384,000
|
-
|
IPR&D
|
3 yrs.
|
110,000
|
110,000
|
-
|
Other intangible
assets
|
5 yrs.
|
246,600
|
196,600
|
50,000
|
|
|
|
|
|
|
$2,406,300
|
$2,277,600
|
$128,700
|
|
Useful
Lives
|
Cost
|
Accumulated
Amortization
|
Net
|
At June 30,
2019:
|
|
|
|
|
|
|
|
|
|
Technology,
trademarks
|
5/10
yrs.
|
$663,800
|
$661,700
|
$2,100
|
Trade
names
|
6 yrs.
|
140,000
|
124,400
|
15,600
|
Websites
|
5 yrs.
|
210,000
|
210,000
|
-
|
Customer
relationships
|
9/10
yrs.
|
357,000
|
308,100
|
48,900
|
Sublicense
agreements
|
10
yrs.
|
294,000
|
224,100
|
69,900
|
Non-compete
agreements
|
5 yrs.
|
384,000
|
384,000
|
-
|
IPR&D
|
3 yrs.
|
110,000
|
110,000
|
-
|
Other intangible
assets
|
5 yrs.
|
221,700
|
183,200
|
38,500
|
|
|
|
|
|
|
$2,380,500
|
$2,205,500
|
$175,000
|
Year Ended June
30,
|
|
|
|
2021
|
$59,800
|
2022
|
36,800
|
2023
|
20,200
|
2024
|
8,400
|
2025
|
3,500
|
|
|
Total
|
$128,700
|
Year ended June
30,
|
Amount
|
|
|
2021
|
$111,000
|
2022
|
95,000
|
2023
|
82,000
|
2024
|
70,000
|
|
|
|
$358,000
|
Year ended June
30,
|
Amount
|
|
|
2021
|
$265,800
|
2022
|
210,600
|
2023
|
198,900
|
2024
|
195,900
|
2025
|
91,600
|
|
|
|
$962,800
|
|
2020
|
2019
|
|
|
|
Computed
“expected” income tax (benefit)
|
$(239,400)
|
$161,700
|
Research and
development credits
|
(89,400)
|
(24,300)
|
Rate changes and
NOL carrybacks
|
(122,600)
|
-
|
Other,
net
|
14,800
|
(12,800)
|
|
|
|
Income tax expense
(benefit)
|
$(436,600)
|
$124,600
|
|
2020
|
2019
|
Deferred tax
assets:
|
|
|
Amortization of
intangible assets
|
$329,700
|
$303,900
|
Research and
development credits
|
89,400
|
-
|
Various
accruals
|
150,700
|
173,600
|
Other
|
19,400
|
13,300
|
|
589,200
|
490,800
|
Deferred tax
liability:
|
|
|
Depreciation of
property and amortization of goodwill
|
(52,100)
|
(59,700)
|
|
|
|
Net deferred tax
assets
|
$537,100
|
$431,100
|
|
June 30,
2020
|
June 30,
2019
|
||
|
|
|
|
|
|
|
Weighted-
|
|
Weighted-
|
|
|
Average
|
|
Average
|
|
|
Exercise
|
|
Exercise
|
|
Shares
|
Price
|
Shares
|
Price
|
Shares under
option:
|
|
|
|
|
Outstanding,
beginning of year
|
97,205
|
$3.24
|
92,000
|
$3.15
|
Granted
|
25,881
|
7.47
|
6,705
|
4.54
|
Exercised
|
(24,000)
|
3.35
|
-
|
-
|
Forfeited
|
(2,500)
|
3.08
|
1,500
|
3.27
|
|
|
|
|
|
Outstanding, end of
year
|
96,586
|
$4.35
|
97,205
|
$3.24
|
|
|
|
|
|
Options exercisable
at year-end
|
49,236
|
$3.29
|
50,167
|
$3.29
|
|
|
|
|
|
Weighted average
fair value per share of options granted during the fiscal
year
|
|
$5.58
|
|
$1.79
|
|
As
of June 30, 2020
Options
Outstanding
|
As
of June 30, 2020
Exercisable
|
|||
|
|
|
|
|
|
|
|
Weighted-
|
|
|
|
|
|
Average
|
Weighted-
|
|
Weighted-
|
Range
|
|
Remaining
|
Average
|
|
Average
|
Exercise
|
Number
|
Contractual
|
Exercise
|
Number
|
Exercise
|
Prices
|
Outstanding
|
Life
(Years)
|
Price
|
Outstanding
|
Price
|
|
|
|
|
|
|
$5.35 - $ 11.30
|
25,881
|
9.87
|
$7.47
|
-
|
$0.00
|
|
|
|
|
|
|
$2.91 - $
4.65
|
70,705
|
6.46
|
$3.33
|
49,236
|
$3.29
|
|
|
|
|
|
|
|
96,586
|
|
|
49,236
|
|
|
As
of June 30, 2019
Options
Outstanding
|
As
of June 30, 2019
Exercisable
|
|||
|
|
|
|
|
|
|
|
Weighted-
|
|
|
|
|
|
Average
|
Weighted-
|
|
Weighted-
|
Range
|
|
Remaining
|
Average
|
|
Average
|
Exercise
|
Number
|
Contractual
|
Exercise
|
Number
|
Exercise
|
Prices
|
Outstanding
|
Life
(Years)
|
Price
|
Outstanding
|
Price
|
|
|
|
|
|
|
$2.91 - $
3.08
|
70,500
|
7.81
|
$3.07
|
30,167
|
$2.80
|
|
|
|
|
|
|
$3.65 - $
4.65
|
26,705
|
5.57
|
$4.02
|
20,000
|
$3.84
|
|
|
|
|
|
|
|
97,205
|
|
|
50,167
|
|
|
2020
|
2019
|
|
|
|
Net income
(loss)
|
$(703,300)
|
$645,600
|
|
|
|
Weighted average
common shares outstanding
|
1,515,103
|
1,494,112
|
Effect of dilutive
securities
|
-
|
18,066
|
|
|
|
Weighted average
dilutive common shares outstanding
|
1,515,103
|
1,512,178
|
|
|
|
Basic and diluted
earnings (loss) per common share
|
$(.46)
|
$.43
|
|
Scientific Industries, Inc.
|
||
|
|
|
|
|
|
|
|
Date: October 09, 2020
|
By:
|
/s/ Helena R. Santos
|
|
|
|
Helena R. Santos
|
|
|
|
Chief Executive Officer and
|
|
|
|
Chief Financial Officer
|
|
|
Scientific Industries, Inc.
|
||
|
|
|
|
|
|
|
|
Date: October 09, 2020
|
By:
|
/s/ Helena R. Santos
|
|
|
|
Helena R. Santos
|
|
|
|
Chief Executive Officer and
|
|
|
|
Chief Financial Officer
|
|
Document and Entity Information - USD ($) |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Oct. 02, 2020 |
|
Document And Entity Information | ||
Entity Registrant Name | SCIENTIFIC INDUSTRIES INC | |
Entity Central Index Key | 0000087802 | |
Document Type | 10-K | |
Document Period End Date | Jun. 30, 2020 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --06-30 | |
Is Entity a Well-known Seasoned Issuer? | No | |
Is Entity a Voluntary Filer? | No | |
Is Entity's Reporting Status Current? | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 2,861,263 | |
Public Float | $ 7,436,000 | |
Document Fiscal Period Focus | FY | |
Document Fiscal Year Focus | 2019 | |
Entity Interactive Data Current | Yes | |
Entity Incorporation State Country Code | DE | |
Entity File Number | 0-6658 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) |
Jun. 30, 2020 |
Jun. 30, 2019 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Allowance doubtful accounts | $ 11,600 | $ 15,000 |
Shareholders' equity: | ||
Common stock,par value | $ 0.05 | $ 0.05 |
Common stock, authorized shares | 7,000,000 | 7,000,000 |
Common stock, issued shares | 2,881,065 | 1,513,914 |
Common stock, outstanding shares | 2,861,263 | 1,494,112 |
Stock held in treasury, shares | 19,802 | 19,802 |
1. Summary of Significant Accounting Policies |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies | Scientific Industries, Inc. and its subsidiaries (the “Company”) design, manufacture, and market a variety of benchtop laboratory equipment, bioprocessing products and catalyst research instruments. The Company is headquartered in Bohemia, New York where it produces benchtop laboratory equipment. Additionally, the Company has two other locations in Pittsburgh, Pennsylvania, where it produces a variety of custom-made catalyst research instruments and designs bioprocessing products, and an administrative facility in Orangeburg, New York related to sales and marketing. The products, which are sold to customers worldwide, include mixers, shakers, stirrers, refrigerated incubators, pharmacy balances and scales, force gauges, catalyst characterization instruments, reactor systems and high throughput systems. The Company also sublicenses certain patents and technology under a license with the University of Maryland, Baltimore County, and receives royalty fees from the sublicenses.
COVID-19 Pandemic
The challenges posed by the COVID-19 pandemic on the global economy began to take effect and impact the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. However, if an employee becomes infected in the future, and the Company is forced to shut down for a period of time, it could have a short-term negative impact on operations. At the beginning of the pandemic, the Catalyst Research Instruments and Bioprocessing Systems Operations were shut down due to state mandates, however, the impact on operations was immaterial, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’ receipt of $563,800 loan under the Federal Government’s Paycheck Protection Program. The Company has not experienced and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies that have the ability to pay. However, there were some delays in receiving some accounts receivable due for catalyst research instruments due to customer shutdowns, and there was a material negative impact on the revenues of the Catalyst Research Instruments. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, supply chain, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, and Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated.
Revenue Recognition
On July 1, 2018 the Company adopted Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”), using the modified retrospective method applied to those contracts which were not completed as of the adoption date. The adoption of the standard did not have a material impact on how the Company recognizes its revenues. In accordance with Topic 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.
Nature of Products and Services
We generate revenues from the following sources: (1) Benchtop Laboratory Equipment, (2) Catalyst Research Instruments, and (3) Royalties.
Benchtop laboratory equipment sales comprise primarily of standard benchtop laboratory equipment from its stock to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. Warranty usually comprises of one to two year parts and labor and is deemed immaterial.
Catalyst research instrument sales comprise primarily of large instruments which begin with a standard model and then are customized to a customer’s specifications. The sales cycle can be quite long, typically ranging from one to three months, from the time an order is received to the time the instrument is shipped to the customer. Payment terms vary from customer to customer and can include advance payments which are recorded as contract liabilities. Some contracts call for training and installation, which is considered ancillary and not a material part of the contract. Due to the size and nature of the instruments, the Company subjects the instruments to an extensive factory acceptance testing process prior to shipment to ensure that they are fully operational once they reach the customer’s site. Normally, the Company warrantees its instruments for a period of twelve months for parts and labor which normally consists of replacement of small components or software support. Catalyst research instruments are never returned for repairs.
Royalty revenues pertain to royalties earned by the Company, which are paid to the Company on a calendar year basis, under a licensing agreement from a single licensee and its sublicensees. The license pertained to royalties received under a United States patent and a European Union patent. As of January 2020, the European Union patent which was due to expire in August 2021, was terminated and the Company will only receive royalties under the United States patent, which will have a material reduction in total royalties expected to be received. The Company is then obligated to pay 50% of all royalties received to the entity that licenses the intellectual property to the Company. During the year, the Company’s management uses its best judgement to estimate the royalty revenues earned during the period.
The Company determines revenue recognition through the following steps:
The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the Financial Accounting Standards Board (“FASB”), in applying ASC Topic 606: 1) All revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) Although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments.
Cash and Cash Equivalents
The Company considers all highly liquid debt instruments purchased with original maturities of 90 days or less to be cash equivalents. At times, cash balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. As of June 30, 2020, and 2019, $6,729,300 and $1,328,600, respectively of cash balances were in excess of such limit.
Accounts Receivable
In order to record the Company’s accounts receivable at their net realizable value, the Company must assess their collectability. A considerable amount of judgment is required in order to make this assessment, including an analysis of historical bad debts and other adjustments, a review of the aging of the Company’s receivables, and the current creditworthiness of the Company’s customers. The Company has recorded allowances for receivables which it considered uncollectible, including amounts for the resolution of potential credit and other collection issues such as disputed invoices, customer satisfaction claims and pricing discrepancies. However, depending on how such potential issues are resolved, or if the financial condition of any of the Company’s customers was to deteriorate and its ability to make required payments became impaired, increases in these allowances may be required. The Company actively manages its accounts receivable to minimize credit risk. The Company does not obtain collateral for its accounts receivable. Based on its assessment, the Company concluded that there are no collection issues related to the COVID-19 Pandemic.
Contract Liabilities
Contract liabilities consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and contract liabilities. The Company invoices its customers in accordance with the terms of the underlying contract. Accordingly, the contract liabilities balance does not represent the total contract value of outstanding arrangements. Contract liabilities that are expected to be recognized during the subsequent 12-month period are recorded as current and the remaining portion as noncurrent. Contract liabilities amounted to $89,000 and $0 at June 30, 2020 and 2019, respectively.
Investment Securities
Investment securities consist of equity securities and mutual funds with realized gains and losses recorded using the specific identification method. Realized gains and losses and changes in fair value are recorded as unrealized holding gains or losses in other income (loss), net on the statement of operations. We determine the cost of the investment sold based on an average cost basis at the individual security level, and record the interest income and realized gains or losses on the sale of these investments in other income (loss), net.
Inventories
Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on management’s review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor and manufacturing overhead.
Property and Equipment
Property and equipment are stated at cost. Depreciation of property and equipment is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the remaining term of the related lease or the estimated useful lives of the assets, whichever is shorter.
Intangible Assets
Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, intellectual property and research and development (“IPR&D”), trademarks and trade names. All intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization.
Goodwill and Long-Lived Assets
Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and long-lived intangible assets are tested for impairment at least annually in accordance with the provisions of ASC No. 350, “Intangibles-Goodwill and Other” (“ASC No. 350”). ASC No. 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The Company tests goodwill and long-lived assets annually as of June 30, the last day of its fiscal year, unless an event occurs that would cause the Company to believe the value is impaired at an interim date. The Company concluded as of June 30, 2020 and 2019, there was no impairment of goodwill.
Impairment of Long-Lived Assets
The Company follows the provisions of ASC No. 360-10, “Property, Plant and Equipment - Impairment or Disposal of Long-Lived Assets (“ASC No. 360-10”). ASC No. 360-10 which requires evaluation of the need for an impairment charge relating to long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation for impairment is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying amount to determine if a write down to a new depreciable basis is required. If required, an impairment charge is recorded based on an estimate of future discounted cash flows. The Company concluded as of June 30, 2020 and 2019, there was no impairment of long-lived assets.
Income Taxes
The Company and its subsidiaries file a consolidated U.S. federal income tax return. Income taxes are accounted for under the asset and liability method. The Company provides for federal, and state income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date.
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
Advertising
Advertising costs are expensed as incurred. Advertising expense amounted to $218,700 and $207,500 for the years ended June 30, 2020 and 2019, respectively.
Research and Development
Research and development costs consisting of expenses for activities that are useful in developing and testing new products, as well as expenses that may significantly improve existing products, are expensed as incurred.
Stock Compensation Plan
The Company has a ten-year stock option plan (the “2012 Plan”) which provides for the grant of options to purchase up to 250,000 shares of the Company’s Common Stock, par value $.05 per share (“Common Stock”), plus up to 57,000 shares under options previously granted under the 2002 Stock Option Plan of the Company (the “Prior Plan”).
The 2012 Plan provides for the granting of incentive or non-incentive stock options as defined in the 2012 Plan and options under the 2012 Plan may be granted until 2022. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Non-incentive stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. At June 30, 2020 and 2019, 147,414 and 20,795 shares respectively, of Common Stock were available for grant of options under the 2012 Plan. The Company has a ten-year stock option plan (the "2012 Plan") which provided for the grant of options to purchase up to 100,000 shares of the Company's Common Stock, par value $.05 per share ("Common Stock") and was further amended in January 2020 to increase the number of options to 250,000 shares of common stock.
Stock-based compensation is accounted for in accordance with ASC No. 718 “Compensation-Stock Compensation” (“ASC No. 718”) which requires compensation costs related to stock-based payment transactions to be recognized. With limited exceptions, the amount of compensation cost is measured based on the grant-date fair value of the equity or liability instruments issued. In addition, liability awards are measured at each reporting period. Compensation costs are recognized over the period that an employee provides service in exchange for the award. During the years ended June 30, 2020 and 2019, the Company granted 25,881 and 6,705 options, respectively, to employees that had a fair value of $144,500 and $12,000, respectively. The fair value of the options granted during the years ended June 30, 2020 and 2019, were determined using the Black-Scholes-Merton option-pricing model. The weighted average assumptions used for the years ended June 30, 2020 and 2019, was an expected life of 10 years; risk free interest rate of .89%% and 2.44%; volatility of 74% and 35%, and dividend yield of .08% and 1.29%, respectively. The Company declared a dividend of $0.05 per share during the year ended June 30, 2019 and none in 2020. The weighted-average value per share of the options granted during the years ended June 30, 2020 and 2019, was $5.58 and $1.79, respectively, and total stock-based compensation costs were $65,800 and $46,800 for the years ended June 30, 2020 and 2019, respectively. Stock-based compensation costs related to nonvested awards expected to be recognized in the future are $113,400 and $38,600 as of June 30, 2020 and 2019, respectively.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation and amortization, assumptions made in valuing equity instruments issued for services, and the fair values of intangibles and goodwill. The actual results experienced by the Company may differ materially from management’s estimates.
Earnings (Loss) Per Common Share
Basic earnings or loss per common share is computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings per common share includes the dilutive effect of stock options, if any.
Recent Accounting Pronouncements
In August 2018, the FASB issued Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. The Company is currently evaluating the impact of adopting this guidance.
In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years; this ASU allows for early adoption in any interim period after issuance of the update. The Company is currently evaluating the impact of adopting this guidance.
Adopted Accounting Pronouncement
In February 2016, the FASB issued ASU No. 2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less. The Company adopted ASU No. 2016-02 on July 1, 2019 using the additional transition method, which allows prior periods to be presented under previous lease accounting guidance. Refer to Note 11, "Leases", for related disclosures. |
2. Segment Information and Concentrations |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information and Concentrations | The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis (“Catalyst Research Instruments Operations”) and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).
Segment information is reported as follows:
|
3. Fair Value of Financial Instruments |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Financial Instruments | The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.
The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:
In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.
The fair value of the contingent consideration obligations is based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following table.
The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis at June 30, 2020 and 2019 according to the valuation techniques the Company used to determine their fair values:
The following table sets forth an analysis of changes during the years ended June 30, 2020 and 2019, respectively, in Level 3 financial liabilities of the Company:
The Company’s contingent obligations require cash payments to the sellers of certain acquired operations based on royalty payments received or operating results achieved. These contingent considerations are classified as liabilities and the liabilities are remeasured to an estimated fair value at each reporting date. During the years ended June 30, 2020 and 2019, the Company recorded an increase in the estimated fair value of contingent liabilities of approximately $112,600 and $521,200, respectively related to its Bioprocessing Systems Operations segment.
Investments in marketable securities classified as available-for-sale by security type at June 30, 2020 and 2019 consisted of the following:
|
4. Inventories |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories |
|
5. Property and Equipment |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment |
Depreciation expense was $88,900 and $67,300 for the years ended June 30, 2020 and 2019, respectively.
|
6. Goodwill and Other Intangible Assets |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets | Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions. Goodwill amounted to $705,300 at June 30, 2020 and 2019, all of which is expected to be deductible for tax purposes.
The components of other intangible assets are as follows:
Total amortization expense was $72,000 and $190,000 in 2020 and 2019, respectively.
Estimated future amortization expense of intangible assets as of June 30, 2020 is as follows:
|
7. Lines of Credit |
12 Months Ended |
---|---|
Jun. 30, 2020 | |
Line of Credit Facility [Abstract] | |
Lines of credit | The Company has a Demand Line of Credit through December 2020 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently 3.25%. The agreement does not contain a financial covenants and borrowings are also secured by a pledge of the Company’s assets including inventory, accounts receivable, chattel paper, equipment and general intangibles of the Company. As of June 30, 2020 and 2019, there were no borrowings outstanding under the line.
|
8. Payroll Protection Program Loan |
12 Months Ended |
---|---|
Jun. 30, 2020 | |
Loans Payable [Abstract] | |
Payroll Protection Program Loan | The Company has a $563,800 Payroll Protection Program loan for proceeds received in April 2020 pursuant to the Paycheck Protection Program loan (“PPP”) administered by the U.S. Small Business Administration through its bank. The loan bears interest at 1% per annum and matures in April 2022 and contains no collateral or guarantee requirements. The Company expects to apply and receive forgiveness for the majority of the loan, for which it will apply in the fiscal year ending June 30, 2021. |
9. Employee Benefit Plans |
12 Months Ended |
---|---|
Jun. 30, 2020 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plans | The Company has a 401(k) profit sharing plan covering all its employees, which provides for voluntary employee salary contributions not to exceed the statutory limitations provided by the Internal Revenue Code. The plan provides for Company matching contribution equal to 100% of employee’s deferral up to 3% of pay, plus 50% of employee’s deferral over 3% of pay up to 5%. Total matching contributions amounted to $84,100 and $69,600 for the years ended June 30, 2020 and 2019, respectively.
|
10. Commitments and Contingencies |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies | The Company has a three-year employment contract with its President, effective July 1, 2017, which was extended by mutual agreement for a one year period ending June 30, 2021. The agreement provided for an annual base salary of $175,000 for the year ended June 30, 2018, with subsequent annual increases of 3% or percentage increase in Consumer Price Index (“CPI”), whichever is higher, plus $25,000 cash bonus for the year ended June 30, 2018, and a discretionary bonus for subsequent years. A bonus of $50,000 was awarded for the year ended June 30, 2020 and none in 2019. The agreement also provided for a grant of options to purchase 25,000 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No shares were granted during the year ended June 30, 2019, and 215,366 shares were authorized to be granted by the Board of Directors during the year ended June 30, 2020 which are subject to amendment to the Company’s 2012 Stock Option Plan. The agreement also contains a provision that within one year of a change of control, if either the Company terminates the employment for any reason other than for "cause" or the Presidents terminates her employment for "good reason", the President will have the right to receive a lump sum payment equal to three times the average of her total annual compensation paid for the last five years preceding such termination, minus $1.00.
The Company has a three-year employment contract with its President of the Genie Products Division of the Benchtop Laboratory Equipment Operations and Corporate Secretary effective July 1, 2017, which was extended by mutual agreement for a one year period ending June 30, 2021. The agreement provides for an annual base salary of $153,000 for the year ended June 30, 2018, with subsequent annual increases of 3% or percentage increase in the CPI, whichever is higher, plus $10,000 cash bonus for the year ended June 30, 2018, and a discretionary bonus for subsequent years. A bonus of $5,000 was awarded for the year ended June 30, 2020 and none in 2019. The agreement also provides for a grant of options to purchase 7,500 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No options were granted during the year ended June 30, 2020 or 2019.
The Company has a three-year employment contract with its President of Torbal Products Division of the Benchtop Laboratory Equipment Operations and Director of Marketing effective July 1, 2017, which was extended by mutual agreement for a one year period ending June 30, 2021. The agreement provides for an annual base salary of $157,000 for the year ended June 30, 2018, with subsequent annual increases of 4% or percentage increase in the CPI, whichever is higher, plus $10,000 cash bonus for the year ended June 30, 2018 and subsequent years, subject to a minimum increase of 5% in the divisions’ EBITDA for the related year. The agreement also provides for a grant of options to purchase 7,500 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No options were granted during the year ended June 30, 2020 or 2019. A performance-based bonus of $10,000 was awarded for each of the years ended June 30, 2018, 2019, and 2020.
The Company has a three-year employment contract with its President of Scientific Bioprocessing, Inc., effective July 1, 2020. The agreement provides for an annual base salary of $175,000 for the year ended June 30, 2021, with subsequent annual increases of 3% or percentage increase in Consumer Price Index (“CPI”), whichever is higher, plus discretionary bonuses. The agreement also provides for a grant of options to purchase 215,366 shares which were authorized to be granted by the Board of Directors during the year ended June 30, 2020, and are subject to amendment to the Company’s 2012 Stock Option Plan. Prior to July 1, 2020, the officer had a consulting agreement through June 30, 2020. Consulting fees paid under this agreement amounted to $145,000 and $40,000 for the years ended June 30, 2020 and 2019, respectively. In addition stock options valued at $36,000 and $12,000 were granted as part of the total compensation under the consulting agreement, for the years ended June 30, 2020 and 2019, respectively. In addition to the fees paid and stock options granted under the consulting agreement, a bonus of $50,000 was awarded during the year ended June 30, 2020 and none in 2019. The agreement contains termination provisions stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if employee resigns for "good reason" (as such term is defined there), the Company shall pay severance payments equal to either one year's salary at the rate of the compensation at the time of termination is employee is terminated within 12 months of the date of the agreement or six months' salary is the employee is terminated after 12 months of the date of the agreement, continue to pay the regular benefits provided by the Company for the period equal tot he length of the severance payments and pay a pro rata portion of any bonus achieved prior to such termination of employment.
The Company had a two-year agreement with its President of Altamira Instruments, Inc. effective July 1, 2017, which was extended by mutual agreement through June 30, 2020, and has not yet been renewed. The agreement provided for an annual base salary of $130,000 and $120,000 for the years ended June 30, 2020 and 2019, respectively, plus incentive pay based on achievement of certain revenue and income levels, which were not achieved in both fiscal years and therefore there was no incentive pay. The agreement also provided for a grant of options for an aggregate of 10,000 shares of the Company’s common stock, which were granted during the year ended June 30, 2018. No shares were granted during the year ended June 30, 2020 or 2019.
The Company had a three-year employment contract with its Vice President of Corporate Development and Strategy and Vice president of Sales and Marketing of Altamira Instruments, Inc. effective July 1, 2017. This agreement was terminated by the Company in February 2020 with termination costs of $180,700, of which $110,900 remains unpaid as of June 30, 2020 and is expected to be paid by February 2021.
The Company has a consulting agreement, which expires on December 31, 2020, with a Director of the Company and his affiliate for product development consulting services. The agreement provides that the consultant be paid a monthly retainer fee of $9,000, plus a grant of 20,000 options during the year ended June 30, 2020. Consulting expense related to this agreement amounted to $76,200 and $43,200 for the years ended June 30, 2020 and 2019, respectively.
On July 20, 2020, the Company entered into a two-year consulting agreement with a new member of the Board of Directors and his affiliate for consulting on strategic matters of the Company’s wholly-owned SBI’s operations. The agreement provides that the consultant be paid a monthly retainer of 5,000 euros, an annual bonus of up to 2% of net sales of the subsidiary’s net sales over mutually agreed upon sales targets, plus the issuance of 125,000 stock options of the Company.
The Company is required to make payments of 30% of the net royalties received from the license and sublicense acquired in the SBI acquisition in fiscal 2014. Total contingent consideration payments made for this acquisition amounted to $372,600 and $311,200 for the years ended June 30, 2020 and 2019, respectively.
The fair value of contingent consideration estimated to be paid as of June 30, 2020 is as follows:
|
11. Leases |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Leases | On July 1, 2019, the Company adopted the new accounting pronouncement as it relates to its leases which requires a lessee to recognize all long-term leases on its balance sheet as a liability for its lease obligation, measured at the present value of lease payments not yet paid, and a corresponding asset representing its right to use the underlying asset over the lease term and expands disclosure of key information about leasing arrangements.
The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) through January 2025, a facility in Pittsburgh, Pennsylvania for its Catalyst Research Instrument Operations through November 2020 and on a month to month thereafter, and another facility in Pittsburgh, Pennsylvania for its Bioprocessing Systems Operations through May 2021. In addition, the Company had a lease for its Torbal Division of the Benchtop Laboratory Equipment Operations which was mutually terminated early effective as of October 31, 2019 and a new lease for a similar sales and administration office in Orangeburg, New York was entered into as of November 1, 2019 through October 2022. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities, and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below. All of the Company’s leases are deemed operating leases.
The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.
The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.
The Company elected available practical expedients for existing or expired contracts of lessees wherein the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption.
As of June 30, 2020, the weighted-average remaining lease term for operating lease liabilities was approximately 3.85 years and the weighted-average discount rate was 5.0%. Total cash payments under these leases were $295,700 for the year ended June 30, 2020, of which $293,500 was recorded as leases expense.
The Company’s approximate future minimum rental payments under all leases existing at June 30, 2020 and 2019, respectively, through January 2025 are as follows:
|
12. Income Taxes |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes | The reconciliation of the provision for income taxes at the federal statutory rate of 21% to the actual tax expense or benefit for the applicable fiscal year was as follows:
Deferred tax assets and liabilities consist of the following:
ASC No. 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC No. 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of June 30, 2020 and 2019, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters.
The Company’s policy is to recognize interest and penalties on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits. The Company is subject to U.S. federal income tax, as well as various state jurisdictions. The Company is currently open to audit under the statute of limitations by the federal and state jurisdictions for the years ended June 30, 2017 and after. The Company does not anticipate any material amount of unrecognized tax benefits within the next 12 months.
|
13. Stock Options |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Options | Option activity is summarized as follows:
|
14. Earnings (Loss) Per Common Share |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings (Loss) Per Common Share | Earnings (loss) per common share data was computed as follows:
Approximately 54,513 and 1,349,850 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended June 30, 2020. Approximately 1,600 shares of the Company's common stock issuable upon the exercise of outstanding options were excluded from the calculation of diluted earnings per share for the year ended June 30, 2019, because they were anti-dilutive. |
15. Equity |
12 Months Ended |
---|---|
Jun. 30, 2020 | |
Stockholders' equity: | |
Equity | On June 18, 2020 the Company entered into a securities purchases agreement with several accredited investors for the sale and issuance of 1,349,850 shares of the Company’s Common Stock at an offering of $4.50 per share and warrants to purchase up to 1,349,850 shares of the Company’s Common Stock at $9.00 per share for total proceeds of $6,074,400. The Company incurred approximately $70,000 in issuance related costs. The proceeds are earmarked for the operations of the Company’s SBI operations. The warrants are immediately exercisable and expire five years from the date of issuance. If at any time commencing twelve months from the date of the agreement, but before the expiration of the warrant, the volume weighted average price of the Company’s Common Stock exceeds $18 per share for each of thirty consecutive days, the Company may at any time in its sole discretion, call for the exercise of the Warrants, in their entirety. |
1. Summary of Significant Accounting Policies (Policies) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nature of Operations | Scientific Industries, Inc. and its subsidiaries (the “Company”) design, manufacture, and market a variety of benchtop laboratory equipment, bioprocessing products and catalyst research instruments. The Company is headquartered in Bohemia, New York where it produces benchtop laboratory equipment. Additionally, the Company has two other locations in Pittsburgh, Pennsylvania, where it produces a variety of custom-made catalyst research instruments and designs bioprocessing products, and an administrative facility in Orangeburg, New York related to sales and marketing. The products, which are sold to customers worldwide, include mixers, shakers, stirrers, refrigerated incubators, pharmacy balances and scales, force gauges, catalyst characterization instruments, reactor systems and high throughput systems. The Company also sublicenses certain patents and technology under a license with the University of Maryland, Baltimore County, and receives royalty fees from the sublicenses. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COVID-19 Pandemic | The challenges posed by the COVID-19 pandemic on the global economy began to take effect and impact the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. However, if an employee becomes infected in the future, and the Company is forced to shut down for a period of time, it could have a short-term negative impact on operations. At the beginning of the pandemic, the Catalyst Research Instruments and Bioprocessing Systems Operations were shut down due to state mandates, however, the impact on operations was immaterial, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’ receipt of $563,800 loan under the Federal Government’s Paycheck Protection Program. The Company has not experienced and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies that have the ability to pay. However, there were some delays in receiving some accounts receivable due for catalyst research instruments due to customer shutdowns, and there was a material negative impact on the revenues of the Catalyst Research Instruments. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, supply chain, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principles of consolidation | The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, and Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Recognition | On July 1, 2018 the Company adopted Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”), using the modified retrospective method applied to those contracts which were not completed as of the adoption date. The adoption of the standard did not have a material impact on how the Company recognizes its revenues. In accordance with Topic 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.
Nature of Products and Services
We generate revenues from the following sources: (1) Benchtop Laboratory Equipment, (2) Catalyst Research Instruments, and (3) Royalties.
Benchtop laboratory equipment sales comprise primarily of standard benchtop laboratory equipment from its stock to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. Warranty usually comprises of one to two year parts and labor and is deemed immaterial.
Catalyst research instrument sales comprise primarily of large instruments which begin with a standard model and then are customized to a customer’s specifications. The sales cycle can be quite long, typically ranging from one to three months, from the time an order is received to the time the instrument is shipped to the customer. Payment terms vary from customer to customer and can include advance payments which are recorded as contract liabilities. Some contracts call for training and installation, which is considered ancillary and not a material part of the contract. Due to the size and nature of the instruments, the Company subjects the instruments to an extensive factory acceptance testing process prior to shipment to ensure that they are fully operational once they reach the customer’s site. Normally, the Company warrantees its instruments for a period of twelve months for parts and labor which normally consists of replacement of small components or software support. Catalyst research instruments are never returned for repairs.
Royalty revenues pertain to royalties earned by the Company, which are paid to the Company on a calendar year basis, under a licensing agreement from a single licensee and its sublicensees. The license pertained to royalties received under a United States patent and a European Union patent. As of January 2020, the European Union patent which was due to expire in August 2021, was terminated and the Company will only receive royalties under the United States patent, which will have a material reduction in total royalties expected to be received. The Company is then obligated to pay 50% of all royalties received to the entity that licenses the intellectual property to the Company. During the year, the Company’s management uses its best judgement to estimate the royalty revenues earned during the period.
The Company determines revenue recognition through the following steps:
The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the Financial Accounting Standards Board (“FASB”), in applying ASC Topic 606: 1) All revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) Although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents | The Company considers all highly liquid debt instruments purchased with original maturities of 90 days or less to be cash equivalents. At times, cash balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. As of June 30, 2020, and 2019, $6,729,300 and $1,328,600, respectively of cash balances were in excess of such limit. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable | In order to record the Company’s accounts receivable at their net realizable value, the Company must assess their collectability. A considerable amount of judgment is required in order to make this assessment, including an analysis of historical bad debts and other adjustments, a review of the aging of the Company’s receivables, and the current creditworthiness of the Company’s customers. The Company has recorded allowances for receivables which it considered uncollectible, including amounts for the resolution of potential credit and other collection issues such as disputed invoices, customer satisfaction claims and pricing discrepancies. However, depending on how such potential issues are resolved, or if the financial condition of any of the Company’s customers was to deteriorate and its ability to make required payments became impaired, increases in these allowances may be required. The Company actively manages its accounts receivable to minimize credit risk. The Company does not obtain collateral for its accounts receivable. Based on its assessment, the Company concluded that there are no collection issues related to the COVID-19 Pandemic.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract Liabilities | Contract liabilities consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and contract liabilities. The Company invoices its customers in accordance with the terms of the underlying contract. Accordingly, the contract liabilities balance does not represent the total contract value of outstanding arrangements. Contract liabilities that are expected to be recognized during the subsequent 12-month period are recorded as current and the remaining portion as noncurrent. Contract liabilities amounted to $89,000 and $0 at June 30, 2020 and 2019, respectively.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investment Securities | Investment securities consist of equity securities and mutual funds with realized gains and losses recorded using the specific identification method. Realized gains and losses and changes in fair value are recorded as unrealized holding gains or losses in other income (loss), net on the statement of operations. We determine the cost of the investment sold based on an average cost basis at the individual security level, and record the interest income and realized gains or losses on the sale of these investments in other income (loss), net. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on management’s review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor and manufacturing overhead.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment | Property and equipment are stated at cost. Depreciation of property and equipment is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the remaining term of the related lease or the estimated useful lives of the assets, whichever is shorter.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets | Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, intellectual property and research and development (“IPR&D”), trademarks and trade names. All intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Long-Lived Assets | Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and long-lived intangible assets are tested for impairment at least annually in accordance with the provisions of ASC No. 350, “Intangibles-Goodwill and Other” (“ASC No. 350”). ASC No. 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The Company tests goodwill and long-lived assets annually as of June 30, the last day of its fiscal year, unless an event occurs that would cause the Company to believe the value is impaired at an interim date. The Company concluded as of June 30, 2020 and 2019, there was no impairment of goodwill.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Impairment of Long-Lived Assets | The Company follows the provisions of ASC No. 360-10, “Property, Plant and Equipment - Impairment or Disposal of Long-Lived Assets (“ASC No. 360-10”). ASC No. 360-10 which requires evaluation of the need for an impairment charge relating to long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation for impairment is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying amount to determine if a write down to a new depreciable basis is required. If required, an impairment charge is recorded based on an estimate of future discounted cash flows. The Company concluded as of June 30, 2020 and 2019, there was no impairment of long-lived assets.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes | The Company and its subsidiaries file a consolidated U.S. federal income tax return. Income taxes are accounted for under the asset and liability method. The Company provides for federal, and state income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date.
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Advertising | Advertising costs are expensed as incurred. Advertising expense amounted to $218,700 and $207,500 for the years ended June 30, 2020 and 2019, respectively.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research and Development | Research and development costs consisting of expenses for activities that are useful in developing and testing new products, as well as expenses that may significantly improve existing products, are expensed as incurred.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Compensation Plan | The Company has a ten-year stock option plan (the “2012 Plan”) which provides for the grant of options to purchase up to 250,000 shares of the Company’s Common Stock, par value $.05 per share (“Common Stock”), plus up to 57,000 shares under options previously granted under the 2002 Stock Option Plan of the Company (the “Prior Plan”).
The 2012 Plan provides for the granting of incentive or non-incentive stock options as defined in the 2012 Plan and options under the 2012 Plan may be granted until 2022. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Non-incentive stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. At June 30, 2020 and 2019, 147,414 and 20,795 shares respectively, of Common Stock were available for grant of options under the 2012 Plan. The Company has a ten-year stock option plan (the "2012 Plan") which provided for the grant of options to purchase up to 100,000 shares of the Company's Common Stock, par value $.05 per share ("Common Stock") and was further amended in January 2020 to increase the number of options to 250,000 shares of common stock.
Stock-based compensation is accounted for in accordance with ASC No. 718 “Compensation-Stock Compensation” (“ASC No. 718”) which requires compensation costs related to stock-based payment transactions to be recognized. With limited exceptions, the amount of compensation cost is measured based on the grant-date fair value of the equity or liability instruments issued. In addition, liability awards are measured at each reporting period. Compensation costs are recognized over the period that an employee provides service in exchange for the award. During the years ended June 30, 2020 and 2019, the Company granted 25,881 and 6,705 options, respectively, to employees that had a fair value of $144,500 and $12,000, respectively. The fair value of the options granted during the years ended June 30, 2020 and 2019, were determined using the Black-Scholes-Merton option-pricing model. The weighted average assumptions used for the years ended June 30, 2020 and 2019, was an expected life of 10 years; risk free interest rate of .89%% and 2.44%; volatility of 74% and 35%, and dividend yield of .08% and 1.29%, respectively. The Company declared a dividend of $0.05 per share during the year ended June 30, 2019 and none in 2020. The weighted-average value per share of the options granted during the years ended June 30, 2020 and 2019, was $5.58 and $1.79, respectively, and total stock-based compensation costs were $65,800 and $46,800 for the years ended June 30, 2020 and 2019, respectively. Stock-based compensation costs related to nonvested awards expected to be recognized in the future are $113,400 and $38,600 as of June 30, 2020 and 2019, respectively.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation and amortization, assumptions made in valuing equity instruments issued for services, and the fair values of intangibles and goodwill. The actual results experienced by the Company may differ materially from management’s estimates.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Common Share | Basic earnings or loss per common share is computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings per common share includes the dilutive effect of stock options, if any.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recent Accounting Pronouncements | In August 2018, the FASB issued Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. The Company is currently evaluating the impact of adopting this guidance.
In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years; this ASU allows for early adoption in any interim period after issuance of the update. The Company is currently evaluating the impact of adopting this guidance.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adopted Accounting Pronouncements | In February 2016, the FASB issued ASU No. 2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less. The Company adopted ASU No. 2016-02 on July 1, 2019 using the additional transition method, which allows prior periods to be presented under previous lease accounting guidance. Refer to Note 11, "Leases", for related disclosures.
|
1. Summary of Significant Accounting Policies (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disaggregation of revenues |
|
2. Segment Information and Concentrations (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment information |
|
3. Fair Value of Financial Instruments (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value inputs |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Analysis of changes in Level 3 financial liabilities |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments in marketable securitites |
|
4. Inventories (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories |
|
5. Property and Equipment (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of property and equipment |
|
6. Goodwill and Other Intangible Assets (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible assets |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated future amortization expense of intangible assets |
|
10. Commitments and Contingencies (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||
Fair value of contingent consideration |
|
11. Leases (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Future minimum rental payments |
|
12. Income Taxes (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax reconciliation |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred tax assets and liabilities |
|
13. Stock Options (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option activity |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options outstanding |
|
14. Earnings (Loss) Per Common Share (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss per common share |
|
1. Summary of Significant Accounting Policies (Details) - USD ($) |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Revenues | $ 8,570,300 | $ 10,199,800 |
Benchtop Laboratory Equipment | ||
Revenues | 6,783,600 | 7,078,800 |
Foreign sales | 2,589,800 | 2,680,300 |
Catalyst Research Instruments | ||
Revenues | 785,900 | 1,814,900 |
Foreign sales | 586,500 | 1,102,300 |
Bioprocessing Systems | ||
Revenues | 1,000,800 | 1,306,100 |
Foreign sales | 1,000,400 | 1,301,200 |
Corporate and Other | ||
Revenues | 0 | 0 |
Foreign sales | 0 | 0 |
Consolidated | ||
Revenues | 8,570,300 | 10,199,800 |
Foreign sales | $ 4,176,700 | $ 5,083,800 |
3. Fair Value of Financial Instruments (Details) - USD ($) |
Jun. 30, 2020 |
Jun. 30, 2019 |
Jun. 30, 2018 |
---|---|---|---|
Assets | |||
Cash and cash equivalents | $ 7,559,700 | $ 1,602,500 | $ 1,053,100 |
Available for sale securities | 331,800 | 330,900 | |
Total | 7,891,500 | 1,933,400 | |
Liabilities: | |||
Contingent consideration | 358,000 | 618,000 | $ 408,000 |
Level 1 | |||
Assets | |||
Cash and cash equivalents | 7,559,700 | 1,602,500 | |
Available for sale securities | 331,800 | 330,900 | |
Total | 7,891,500 | 1,933,400 | |
Liabilities: | |||
Contingent consideration | 0 | 0 | |
Level 2 | |||
Assets | |||
Cash and cash equivalents | 0 | 0 | |
Available for sale securities | 0 | 0 | |
Total | 0 | 0 | |
Liabilities: | |||
Contingent consideration | 0 | 0 | |
Level 3 | |||
Assets | |||
Cash and cash equivalents | 0 | 0 | |
Available for sale securities | 0 | 0 | |
Total | 0 | 0 | |
Liabilities: | |||
Contingent consideration | $ 358,000 | $ 618,000 |
3. Fair Value of Financial Instruments (Details 1) - USD ($) |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Fair Value Disclosures [Abstract] | ||
Beginning balance | $ 618,000 | $ 408,000 |
Increase in contingent consideration liability | 112,600 | 521,200 |
Payments | (372,600) | (311,200) |
Ending balance | $ 358,000 | $ 618,000 |
3. Fair Value of Financial Instruments (Details 2) - USD ($) |
Jun. 30, 2020 |
Jun. 30, 2019 |
---|---|---|
Cost | $ 327,900 | $ 339,400 |
Fair value | 331,800 | 330,900 |
Unrealized holding gain (loss) | 3,900 | (8,500) |
Equity Securities | ||
Cost | 77,600 | 47,100 |
Fair value | 101,900 | 72,000 |
Unrealized holding gain (loss) | 24,300 | 24,900 |
Mutual Funds | ||
Cost | 250,300 | 292,300 |
Fair value | 229,900 | 258,900 |
Unrealized holding gain (loss) | $ (20,400) | $ (33,400) |
4. Inventories (Details) - USD ($) |
Jun. 30, 2020 |
Jun. 30, 2019 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw materials | $ 1,838,500 | $ 1,738,300 |
Work-in-process | 228,600 | 106,400 |
Finished goods | 817,600 | 747,600 |
Inventory | $ 2,884,700 | $ 2,592,300 |
5. Property and Equipment (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 88,900 | $ 67,300 |
6. Goodwill and Other Intangible Assets (Details) - USD ($) |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Cost | $ 2,406,300 | |
Accumulated amortization | 2,277,600 | |
Net | 128,700 | $ 175,000 |
Technology, trademarks | ||
Cost | 664,700 | 663,800 |
Accumulated amortization | 662,000 | 661,700 |
Net | $ 2,700 | $ 2,100 |
Technology, trademarks | Minimum | ||
Useful life | 5 years | 5 years |
Technology, trademarks | Maximum | ||
Useful life | 10 years | 10 years |
Trade names | ||
Cost | $ 140,000 | $ 140,000 |
Accumulated amortization | 140,000 | 124,400 |
Net | $ 0 | $ 15,600 |
Useful life | 6 years | 6 years |
Websites | ||
Cost | $ 210,000 | $ 210,000 |
Accumulated amortization | 210,000 | 210,000 |
Net | $ 0 | $ 0 |
Useful life | 5 years | 5 years |
Customer relationships | ||
Cost | $ 357,000 | $ 357,000 |
Accumulated amortization | 321,400 | 308,100 |
Net | $ 35,600 | $ 48,900 |
Customer relationships | Minimum | ||
Useful life | 9 years | 9 years |
Customer relationships | Maximum | ||
Useful life | 10 years | 10 years |
Sublicense agreements | ||
Cost | $ 294,000 | $ 294,000 |
Accumulated amortization | 253,600 | 224,100 |
Net | $ 40,400 | $ 69,900 |
Useful life | 10 years | 10 years |
Non-compete agreements | ||
Cost | $ 384,000 | $ 384,000 |
Accumulated amortization | 384,000 | 384,000 |
Net | $ 0 | $ 0 |
Useful life | 5 years | 5 years |
IPR and D | ||
Cost | $ 110,000 | $ 110,000 |
Accumulated amortization | 110,000 | 110,000 |
Net | $ 0 | $ 0 |
Useful life | 3 years | 3 years |
Other intangible assets | ||
Cost | $ 246,600 | $ 221,700 |
Accumulated amortization | 196,600 | 183,200 |
Net | $ 50,000 | $ 38,500 |
Useful life | 5 years | 5 years |
6. Goodwill and Other Intangible Assets (Details 1) - USD ($) |
Jun. 30, 2020 |
Jun. 30, 2019 |
---|---|---|
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2021 | $ 59,800 | |
2022 | 36,800 | |
2023 | 20,200 | |
2024 | 8,400 | |
2025 | 3,500 | |
Total | $ 128,700 | $ 175,000 |
6. Goodwill and Other Intangible Assets (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Goodwill | $ 705,300 | $ 705,300 |
Total amortization expense | $ 72,000 | $ 190,000 |
10. Commitments and Contingencies (Details 1) |
Jun. 30, 2020
USD ($)
|
---|---|
Commitments and Contingencies Disclosure [Abstract] | |
2021 | $ 111,000 |
2022 | 95,000 |
2023 | 82,000 |
2024 | 70,000 |
Total | $ 358,000 |
11. Leases (Details) |
Jun. 30, 2020
USD ($)
|
---|---|
Leases [Abstract] | |
2021 | $ 265,800 |
2022 | 210,600 |
2023 | 198,900 |
2024 | 195,900 |
2025 | 91,600 |
Total present value of operating lease liabilities | $ 962,800 |
11. Leases (Details Narrative) |
12 Months Ended |
---|---|
Jun. 30, 2020
USD ($)
| |
Leases [Abstract] | |
Weighted-average remaining lease term | 3 years 10 months 6 days |
Weighted-average discount rate | 5.00% |
Total cash payments under leases | $ 295,700 |
Lease expense | $ 293,500 |
12. Income Taxes (Details) - USD ($) |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Income Tax Disclosure [Abstract] | ||
Computed "expected" income tax (benefit) | $ (239,400) | $ 161,700 |
Research and development credits | (89,400) | (24,300) |
Change in tax rate | (122,600) | 0 |
Other, net | 14,800 | (12,800) |
Income tax expense (benefit) | $ (436,600) | $ 124,600 |
12. Income Taxes (Details 1) - USD ($) |
Jun. 30, 2020 |
Jun. 30, 2019 |
---|---|---|
Deferred tax assets: | ||
Amortization of intangibles | $ 329,700 | $ 303,900 |
Research and development credits | 89,400 | 0 |
Various accruals | 150,700 | 173,600 |
Other | 19,400 | 13,300 |
Gross | 589,200 | 490,800 |
Deferred tax liability: | ||
Depreciation of property and amortization of goodwill | (52,100) | (59,700) |
Net deferred tax assets | $ 537,100 | $ 431,100 |
13. Stock Options (Details) - $ / shares |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Share-based Payment Arrangement [Abstract] | ||
Number of Options Outstanding, Beginning | 97,205 | 92,000 |
Number of Options Granted | 25,881 | 6,705 |
Number of Options Exercised | (24,000) | 0 |
Number of Options Forfeited | (2,500) | 1,500 |
Number of Options Outstanding, Ending | 96,586 | 97,205 |
Number of Options Exercisable | 49,236 | 50,167 |
Weighted Average Exercise Price Outstanding, Beginning | $ 3.24 | $ 3.15 |
Weighted Average Exercise Price Granted | 7.47 | 4.54 |
Weighted Average Exercise Price Exercised | 3.35 | 0 |
Weighted Average Exercise Price Forfeited | 3.08 | 3.27 |
Weighted Average Exercise Price Outstanding, Ending | 4.35 | 3.24 |
Weighted Average Exercise Price Exercisable | 3.29 | 3.29 |
Weighted average fair value per share of options granted | $ 5.58 | $ 1.79 |
14. Earnings (Loss) Per Common Share (Details) - USD ($) |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Earnings Per Share [Abstract] | ||
Net income (loss) | $ (703,300) | $ 645,600 |
Weighted average common shares outstanding | 1,515,103 | 1,494,112 |
Effect of dilutive securities | 0 | 18,066 |
Weighted average dilutive common shares outstanding | 1,515,103 | 1,512,178 |
Basic and diluted earnings (loss) per common share | $ (.46) | $ 0.43 |
13. Earnings (Loss) Per Common Share (Details Narrative) - shares |
12 Months Ended | |
---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Earnings Per Share [Abstract] | ||
Common stock issuable upon the exercise of stock options and warrants | 54,513 | 1,349,850 |
Common stock issuable upon the exercise of outstanding options | 0 | 1,600 |
S/?_I(H6S>TZ P]%0$ABFG'L3#PI7!KN"0L-<]2%MQPFQ9[C&6/
MD3^",&ULC57;
M;MLP#'WO5Q!>.VQ $#M.>ET2H.DZK ,*!.TN#\,>%)N)A F]DIJG%IP=5D*NYZ@,JM1U(NV&W=R
M47C>B,?#2BSP'OV/:FK)BEN47):HG30:+,Y'T67O8C)@_^#P4^+*[:R!E
^<)$E0QJ58H[!T'=PB0 \;&JLK];@+=CU6%N\P$G*AI =[/E++-#3%H
M?TAS\3]02P,$% @ 2/+DA4!
MQC]KG;W.) ON?F^T_QI\AR]3X>2-*?]4A5]<]$YZ5,B9:$I_:Y:_R;4_8]:7
MF]*%O[1L[V99C_+&>5.MA8&@4KK]%8]K'G8$3N)G!-*U0!IPMX8"RM?"B\MS
M:Y9D^3:T\4=P-4@#G-(